MedAvail (MDVLQ) 10-K 29 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36533
Entity Registrant Name	MEDAVAIL HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772394
Entity Address, Address Line One	6665 Millcreek Dr.
Entity Address, Address Line Two	Unit 1
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5N 5M4
City Area Code	905
Local Phone Number	812-0023
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MDVL
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Emerging Growth	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 399.2
Entity Common Stock, Shares Outstanding		32,908,922
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE: Portions of the registrant’s Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2021.
Entity Central Index Key	0001402479
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Oakville, Ontario, Canada
Auditor Firm ID	271

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 19,689	$ 57,936
Restricted cash	400	60
Accounts receivable (net of allowance for doubtful accounts of $66 thousand for 2021 and $40 thousand for 2020)	1,189	1,520
Inventories	3,916	2,817
Prepaid expenses and other current assets	2,191	1,534
Total current assets	27,385	63,867
Property, plant and equipment, net	5,692	3,795
Intangible assets, net	2,300	227
Right-of-use assets	2,538	1,239
Other assets	228	203
Total assets	38,143	69,331
Current liabilities:
Accounts payable and accrued liabilities	6,740	4,512
Short-term debt	0	2,161
Deferred revenue	83	275
Current portion of lease obligations	682	665
Total current liabilities	7,505	7,613
Long-term debt	9,538	0
Long-term portion of lease obligations	2,027	651
Total liabilities	19,070	8,264
Commitments and contingencies (Note 18)
Stockholders' equity (deficit):
Common shares ($0.001 par value, 100,000,000 shares authorized, 32,902,048 and 31,816,020 shares issued and outstanding at December 31, 2021 and 2020, respectively)	33	32
Warrants	1,373	2,614
Additional paid-in-capital	216,685	213,624
Accumulated other comprehensive loss	(6,928)	(6,928)
Accumulated deficit	(192,090)	(148,275)
Total shareholders’ equity	19,073	61,067
Total liabilities and shareholders’ equity	$ 38,143	$ 69,331

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 66	$ 40
Common shares, par value (in USD per share)	$ 0.001	$ 0.001
Common shares, authorized (in shares)	100,000,000	100,000,000
Common shares, issued (in shares)	32,902,048	31,816,020
Common shares, outstanding (in shares)	32,902,048	31,816,020

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 22,129	$ 13,968
Cost of products sold and services:
Total cost of products sold and services	21,812	8,805
Operating expense:
Pharmacy operations	13,496	6,146
General and administrative	22,277	15,863
Selling and marketing	7,204	3,283
Research and development	849	682
Merger expenses	0	4,691
Total operating expense	43,826	30,665
Operating loss	(43,509)	(25,502)
Other income (loss), net	206	(110)
Interest income	79	43
Interest expense	(589)	(1,241)
Loss before income taxes	(43,813)	(26,810)
Income tax expense	(2)	0
Net loss	(43,815)	(26,810)
Foreign currency translation adjustment	0	22
Total comprehensive loss	$ (43,815)	$ (26,788)
Net loss per share - basic (in USD per share)	$ (1.34)	$ (4.69)
Net loss per share - diluted (in USD per share)	$ (1.34)	$ (4.69)
Weighted average shares outstanding - diluted (in shares)	32,656,325	5,722,095
Weighted average shares outstanding - basic (in shares)	32,656,325	5,722,095
Pharmacy and hardware revenue
Revenue:
Total revenue	$ 21,119	$ 10,596
Cost of products sold and services:
Total cost of products sold and services	21,306	8,593
Service revenue
Revenue:
Total revenue	1,010	3,372
Cost of products sold and services:
Total cost of products sold and services	$ 506	$ 212

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Deficit) - USD ($) $ in Thousands		Total	Common Shares	Treasury Stock	Warrants	Additional Paid-in-Capital	Accumulated Equity (Deficit)	Accumulated Other Comprehensive Loss
Temporary equity beginning balance (in shares) at Dec. 31, 2019	[1]	10,500,440
Temporary equity beginning balance at Dec. 31, 2019	[1]	$ 93,484
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of preferred shares (in shares)	[1]	102,777
Issuance of preferred shares	[1]	$ 788
Conversion of preferred shares (in shares)	[1]	(10,603,217)
Conversion of preferred shares	[1]	$ (94,272)
Temporary equity ending balance (in shares) at Dec. 31, 2020	[1]	0
Temporary equity ending balance at Dec. 31, 2020	[1]	$ 0
Balance at beginning of period (in shares) at Dec. 31, 2019			1,504,251	0
Balance at beginning of period at Dec. 31, 2019			$ 8		$ 698	$ 30,829	$ (121,230)	$ (6,950)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(26,810)					(26,810)
Shares issued in transaction (in shares)			12,336,913
Shares issued		83,902	$ 12			83,890
Conversion of debt (in shares)			1,924,995
Conversion of debt		13,090	$ 2			13,088
Conversion of preferred shares (in shares)			14,866,151
Conversion of preferred shares			$ 15			94,257
Issuance of common shares in connection with merger (in shares)			1,015,983
Issuance of common shares in connection with merger		0	$ 1			(1)
Exercise of warrants (in shares)			7,635
Exercise of warrants		$ 12			12
Shares issued for options exercises (in shares)		160,090	160,092
Shares issued for options exercises		$ 313				313
Share-based compensation		380				380
Purchase of treasury stock (in shares)			67,188	67,188
Purchase of treasury stock		(892)					(892)
Issuance of treasury stock for options exercise (in shares)			67,188	67,188
Issuance of treasury stock for options exercise		657					657
Warrants issued		1,439			1,904	(465)
Stock offering expense		(3,658)				(3,658)
Cumulative translation adjustment		22						22
Consideration paid in merger		(5,000)				(5,000)
Adjustments related to merger		(15)	$ (6)			(9)
Balance at end of period (in shares) at Dec. 31, 2020			31,816,020	0
Balance at end of period at Dec. 31, 2020		61,067	$ 32		2,614	213,624	(148,275)	(6,928)
Total equity and temporary equity at beginning of period at Dec. 31, 2019		(3,161)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity and temporary equity, conversion of preferred shares		0
Total equity and temporary equity at end of period at Dec. 31, 2020		$ 61,067
Temporary equity ending balance (in shares) at Dec. 31, 2021	[1]	0
Temporary equity ending balance at Dec. 31, 2021	[1]	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(43,815)					(43,815)
Exercise of warrants (in shares)			794,804
Exercise of warrants		$ 151	$ 1		(1,241)	1,391
Shares issued for options exercises (in shares)		237,330	248,485
Shares issued for options exercises		$ 393				393
Share-based compensation		1,205				1,205
Cumulative translation adjustment		0
ESPP		72				72
Balance at end of period (in shares) at Dec. 31, 2021			32,902,048	0
Balance at end of period at Dec. 31, 2021		19,073	$ 33		$ 1,373	$ 216,685	$ (192,090)	$ (6,928)
Total equity and temporary equity at end of period at Dec. 31, 2021		$ 19,073
[1]	$0.001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (43,815)	$ (26,810)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	1,174	1,016
Amortization of intangible and leased assets	1,403	789
Bad debt and other non-cash receivables adjustments	83	242
Term loan discount amortization and interest accretion on debt	162	1,455
Unrealized foreign currency loss	0	21
Share-based compensation expense	1,205	380
Provisions for inventory	626	219
PPP loan forgiveness gain	(161)	0
Changes in operating assets and liabilities:
Change in accounts receivable	248	(1,346)
Change in inventory	(3,542)	36
Change in prepaid expenses and other assets	(657)	(1,418)
Change in accounts payable, accrued expenses, and other liabilities	1,603	1,892
Change in deferred revenue	(192)	(4,529)
Change in operating lease liability due to cash payments	(656)	(581)
Net cash used in operating activities	(42,519)	(28,634)
Cash flows from investing activities:
Purchase of property, plant and equipment	(841)	(662)
Purchase of intangible assets	(2,448)	(155)
Payment of security deposits	(25)	0
Net cash used in investing activities	(3,314)	(817)
Net cash flows from financing activities:
Issuance of common shares in private placement	0	83,900
Issuance of preferred shares	0	788
Issuance of common shares	0	50
Issuance of common shares upon exercise of options and warrants	616	275
Issuance of warrants	0	481
Proceeds from debt	10,000	12,994
Payment of debt issuance costs	(624)	0
Repayment of debt	(2,000)	(14,134)
Payments on financing lease obligations	(66)	0
Cash paid for offering expenses	0	(3,658)
Cash consideration in conjunction with Merger	0	(2,000)
Other financing activities	0	(98)
Net cash provided by financing activities	7,926	78,598
Net (decrease) increase in cash, cash equivalents, and restricted cash	(37,907)	49,147
Cash, cash equivalents, and restricted cash at beginning of period	57,996	8,849
Cash, cash equivalents, and restricted cash at end of period	20,089	57,996
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Conversion of debt into common shares	0	13,088
Conversion of preferred shares into common shares	0	94,257
Note issued as consideration in conjunction with Merger	0	3,000
Purchase of treasury stock	0	233
Inventory transferred to property, plant and equipment	1,817	1,520
Property, plant and equipment transferred to intangible assets	42	0
Purchases of intangible assets in accounts payable	241	72
Purchases of property, plant and equipment in accounts payable	455	0
Lease Liabilities Arising From Obtaining Right-Of-Use Assets [Abstract]
Operating leases	2,179	737
Finance leases	$ 97	$ 168

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Deficit) ( (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Redeemable preferred shares, par value (in USD per share)	$ 0.001	$ 0.001
Redeemable preferred shares, authorized (in shares)	10,000,000	10,000,000

NATURE OF OPERATIONS

NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation formerly known as MYOS RENS Technology, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, kiosk and drive-thru solution. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. The Company also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology. Merger Agreement On June 30, 2020, MYOS RENS Technology Inc., a Nevada corporation, or MYOS, and MedAvail, Inc., or MAI, a Delaware corporation based in Canada, entered into an Agreement and Plan of Merger and Reorganization, or Merger Agreement, by and among MYOS, MAI, and Matrix Merger Sub, Inc., a newly-created wholly-owned subsidiary of MYOS, or Merger Sub, pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub merged with and into MAI, with MAI being the surviving corporation and a wholly-owned subsidiary of MYOS, or the Merger. The Boards of Directors of MYOS and MAI both approved the Merger and recommended approval of the Merger by their respective shareholders. Immediately prior to the merger, Private Placement Shares were sold by MAI to certain subscribers in a total of $83.9 million. These shares were converted to common shares of the Post-Merger Public Company shares immediately following the merger. At November 17, 2020, the effective time of the Merger, or Effective Time: (a) each share of MAI’s common stock and each share of MAI’s preferred stock outstanding immediately prior to the Effective Time, excluding any dissenting shares, was automatically converted solely into the right to receive a number of shares of MYOS common stock, or “MYOS Common Stock”, calculated according to the exchange ratio described below; (b) each outstanding MAI stock option that was not exercised prior to the Effective Time was assumed by MYOS; and (c) each outstanding warrant to acquire MAI capital stock that was not exercised prior to the Effective Time was assumed by MYOS. Under the exchange ratio formula in the Merger Agreement, as of immediately after the Merger, the former MAI security holders owned approximately 96.8% of the aggregate number of fully-diluted shares of MYOS Common Stock outstanding following the consummation of the Merger, or the Post-Closing Shares, and the shareholders of MYOS immediately prior to the Merger owned approximately 3.2% of the Post-Closing Shares, subject to the adjustments set forth in the Merger Agreement. The exchange ratio was fixed prior to the closing of the Merger to reflect MYOS’s and MAI’s respective capitalizations as of immediately prior to the Effective Time. The Merger qualifies for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended. Immediately following the Merger, the name of the post-merger combined company, or the Post-Merger Combined Company, was changed from “MYOS RENS Technology Inc.” to “MedAvail Holdings, Inc.” The Merger Agreement provided that the Board of Directors of the Post-Merger Combined Company consists of members who were directors of MAI immediately prior to the Merger. The executive officers of the Post-Merger Combined Company were designated by MAI, and are MAI’s executive officers from immediately preceding the Merger. Accounting For Merger The Merger was treated as a reverse recapitalization effected by a share exchange for financial accounting and reporting purposes since substantially all of MYOS’s operations were disposed of immediately following the consummation of the Merger as a stock dividend to former MYOS shareholders. In connection with the Merger, MAI paid cash of $2.0 million and issued a $3.0 million promissory note, of which, the first payment of $1.0 million was made at closing, to MYOS, Inc, and the remaining payments were made during 2021. The assets and liabilities and the historical operations that are reflected in these consolidated financial statements are those of MAI as if MAI had always been the reporting company. All reference to MedAvail Holdings, Inc. shares of common stock, warrants and options have been presented on a Post-Merger, post-reverse split basis. Equity is also that of MAI, with an adjustment for the fair value of the accounting acquiree, which, due to the disposal of the historical assets and liabilities, consists only of the cash and promissory note issued to MYOS Corp. Expenses related to the Merger were expensed as incurred. Certain expenses were incurred in conjunction with the private placement stock offering, and such expenses were recorded as a cost of issuing equity and reported in additional paid-in-capital.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	GOING CONCERN The consolidated financial statements for the years ended December 31, 2021 and 2020 were prepared on the basis of a going concern which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. Accordingly, they do not give effect to adjustments that would be necessary should the Company be required to liquidate its assets. Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company’s ability to continue as a going concern. If substantial doubt does exist management should determine if there are plans in place which alleviate that doubt. Since inception through December 31, 2021, the Company continually incurred losses from its operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. As of December 31, 2021, the Company had $19.7 million in cash and cash equivalents and an accumulated deficit of $192.1 million. Furthermore, net cash used in operating activities for the years ended December 31, 2021 and 2020 was $42.5 million and $28.6 million, respectively. Due to the Company’s significant and ongoing cash requirements to fund its operations, management determined that there is substantial doubt as to the Company’s ability to continue as a going concern. The Company added to its liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 13, pursuant to which we borrowed $10.0 million in aggregate initial term loans and under which the Company may borrow up to an additional $20.0 million in aggregate term loans on or before April 30, 2022. In addition, the Company plans to raise additional funding through public or private equity or debt financings. There can be no assurance that the steps management is taking will be successful. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue its development and expansion plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development and deployment of its MedCenter kiosks and SpotRx pharmacy operations and its ability to raise significant additional funding.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Basis of Presentation The consolidated financial statements include the accounts of all subsidiaries of the Company with intercompany transactions and balances eliminated on consolidation. All of the Company’s subsidiaries are wholly owned. These consolidated financial statements have been prepared by management in accordance with United States generally accepted accounting principles (“U.S. GAAP”) on a basis consistent for all periods presented. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, impairment of long-lived assets; and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are deemed to be necessary. Risks and Uncertainties relating to COVID-19 The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and known and unknown impacts of COVID-19 as of December 31, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the recoverability of the Company’s, PPE and intangible assets, net realizable value of inventory, and recoverability of right-of-use operating lease assets. As of the date of issuance of the financial statements, the Company is not aware of any additional events or circumstances which would require it to update its estimates, judgments, or revise the carrying value of its assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and such changes will be recognized in the consolidated financial statements as soon as they become known. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements. Fiscal years ended December 31, 2021 and December 31, 2020, respectively, may be referred to as 2021 and 2020. Amounts presented in these consolidated financial statements are in United States dollars unless otherwise indicated. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our accounting policies are set forth in Note 4. Significant Accounting Policies. Principles of consolidation The consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. MedAvail Technologies Inc., MedAvail Technologies (US) Inc., MedAvail Pharmacy Inc., and MedAvail, Inc. are all subsidiaries of the Company. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. Stock split As part of the Merger transaction and as discussed in Note 19 below, the Company recorded a 1.26 for 1 split for its common shares. All share and per share amounts have been recalculated and presented to reflect the split. Reclassifications During the year, management reclassified certain operating expenses to reflect the costs attributable to pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact on the operating loss subtotal within the consolidated statements of operations and comprehensive loss. The effect of the reclassifications within the consolidated statement of operations and comprehensive loss for 2020 is as follows (in thousands): Year Ended December 31, 2020 Current presentation As previously reported Change Pharmacy operations $ 6,146 $ 5,687 $ 459 General and administrative 15,863 16,562 (699) Selling and marketing 3,283 3,043 240 $ 25,292 $ 25,292 $ —

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents The Company classifies all highly liquid instruments with an original maturity of three months or less as cash equivalents. The Company’s cash and cash equivalents generally include funds held in checking and savings accounts at large American and Canadian financial institutions and denominated in U.S. Dollars and Canadian Dollars. Restricted Cash The Company considers cash to be restricted when withdrawal or general use is legally restricted. During 2020 the Company maintained a balance with the issuer of certain purchasing cards as a guarantee for those cards. During the year ended December 31, 2021, MedAvail recovered the prior $0.06 million restricted cash balance that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicone Valley Bank (See Note 13), MedAvail issued letters of credit to secure certain operating leases, and MedAvail is required to maintain a $0.40 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposits, the balances were classified as restricted cash. Restricted cash was included in the balance for cash presented in the statements of cash flows. Accounts Receivable Accounts receivable are primarily comprised of trade receivables presented net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts based on its assessment of the collectability of amounts owed by customers. The allowance consists of known specific troubled accounts as well as an amount based on overall estimated potential uncollectible accounts receivable based on historical experience. At December 31, 2021 and 2020, the allowance for doubtful accounts had a balance of $0.1 million and $0.0 million, respectively. At December 31, 2020, the balances due from employees were $0.3 million, which were included in accounts receivable. No balances were due from employees at December 31, 2021. Prepaid expenses and other current assets Prepaid expenses and other current assets consist primarily of prepaid amounts for insurance, rent and general operating expenses. Research and Development Research and development expenses represent costs incurred to internally develop and innovate the MedCenter platform technology, including research and development on the MedCenter kiosk hardware, and related software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs. The Company does not incur research and development for others or provided such services to external parties. When research and development costs are incurred to develop hardware, the costs are expensed until technological feasibility is achieved, at which point the costs are capitalized. Software Software development costs are accrued and expensed based on ASC 985 or ASC 350 for external and internal use software, respectively. External use software includes software costs for applications that the Company intends to sell or lease (in conjunction with related hardware). Internal use software includes software costs for applications that are used internally. Any software development costs that are incurred prior to the point where the project has demonstrated technological feasibility are expensed as they are incurred. Once technological feasibility has been established, development costs are capitalized. Once development is complete and the software is made available for release to customers, capitalization is no longer appropriate because any remaining costs are considered ongoing maintenance and support. These are expensed as they are incurred. The definition of “technological feasibility”, per ASC 985 or ASC 350, is “the technological feasibility of a computer software product is established when the entity has completed all planning, designing, coding, and testing activities that are necessary to establish that the product can be produced to meet its design specifications including functions, features, and technical performance requirements.” Software development costs are subject to these rules regardless of whether the costs were generated internally (employee time) or externally (vendor fees). Foreign Currency Translation The functional currency for all our subsidiaries is the U.S. dollar. Gains and losses resulting from the remeasurement of foreign currency amounts to the functional currency are included in operating expenses in the consolidated statements of comprehensive loss. Gains and losses resulting from translating assets and liabilities from the functional currency to U.S. dollars are included in Foreign currency translation adjustment in the consolidated statements of operations and comprehensive loss. Government Grants The Company accounts for government grants and loans as debt until it is reasonably assured that all or a portion of the loan will be forgiven, often indicated by a notice received from the government agency in question that the amount has been forgiven. At that time, the amount that is forgiven is converted from debt and recognized as grant income. The Company does not impute interest on government loans if the rate is determined to be below-market due to the scope exemption for government-mandated interest rates. Convertible Debt The Company accounts for convertible debt and related transactions in accordance with ASC 470-20, Debt with Conversion and Other Options, ASC 815, Derivatives and Hedging, and ASC 480, Distinguishing Liabilities from Equity. The Company evaluates convertible debt instruments and related transactions at inception to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. Convertible debt instruments that may be settled in cash are separated into liability and equity components. The allocation to the liability component is based on the fair value of a similar instrument that does not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs are then allocated to the liability and equity components in a similar manner. The difference between the principal amount of the convertible debt instruments and the liability component, inclusive of issuance costs, represents the debt discount, which is amortized to interest expense over the term of instruments. The determination of the discount rate requires certain estimates and assumptions. Pharmacy Technology Revenue Recognition The Company accounts for revenue under Accounting Standards Codification, or ASC, Topic 606: Revenue from Contracts with Customers, or Topic 606. The amount of revenue recognized for any goods or services reflects the consideration that the Company expects to be entitled to receive in exchange for those goods and services. To achieve this core principle, the Company applies the following five-step approach: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as a performance obligation is satisfied. A contract is accounted for when approved by both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Performance obligations under a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. In certain instances, the Company concluded that distinct goods or services should be accounted for as a single performance obligation that is a series of distinct goods or services that have the same pattern of transfer to the customer. The transaction price is determined based on the consideration that the Company will be entitled to in exchange for transferring goods or services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price, utilizing the expected value method. During 2021 and 2020, none of our pharmacy technology contracts included variable consideration. Determining the transaction price requires judgment. The Company must also determine if the promises to transfer the goods or services to the customer are separately identifiable from other promises in the contract (the goods or services are distinct in the context of the contract). If these criteria are not met, the promised services are accounted for as a single performance obligation. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price (SSP) basis. We determine each SSP based on the Company’s history of selling such performance obligations as standalone goods or services. When no observable evidence exists, we estimate SSP using cost-plus method. In cases where the cost-plus method is used, to establish the gross margins we utilize all observable data points including, market and industry data points and the Company’s pricing practices. Subscription Revenue The Company provides MedCenter units to customers on a contract that includes software license and maintenance services or a Subscription Agreement. Subscription Agreements include operating leases for the MedCenter units with a non-cancelable term of 12 months or less, and are recorded following lessor guidance for operating leases. MedCenters leased to customers are carried on the Company’s consolidated balance sheets as MedCenter equipment and depreciated. For the years ended December 31, 2021 and 2020, subscription revenue was $0.4 million and $0.5 million, respectively, within the pharmacy and hardware revenue on the consolidated statements of operations and comprehensive loss. MedCenter Revenue The Company derives revenue from the sale of MedPlatform Systems, which include MedCenter prescription dispensing kiosks, and the associated installation, software, maintenance and support, and professional service components necessary for operation, representing multiple distinct performance obligations. Hardware and installation revenue is recognized when the MedCenter is delivered, installed, and controlled by the customer. Software, and maintenance and support revenue is recognized over the term of the MedCenter Systems contract. Professional service revenue is recognized on a proportional performance, time-and-materials basis, as the services are delivered to the customer. For any consideration received prior to the fulfillment of the obligation, deferred revenue is recorded. As of December 31, 2021 and 2020, the consolidated balance sheets included $0.1 million and $0.3 million, respectively, of deferred revenue. Retail Pharmacy Revenue Recognition The Company recognizes revenue, net of sales taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. Revenue from the sale of the pharmaceutical products is recorded at a transaction price which includes an estimate of direct and indirect remuneration fees or DIR fees associated with prescription drugs dispensed during the year. DIR fees are calculated by pharmacy benefit managers or PBMs after the sale is completed pursuant to contract terms. The DIR fees under these arrangements are estimated at the time of sale and recognized as a reduction in revenue. Management developed the estimated provisions for revenue reserves based on historical trends adjusted for product mix and PBM mix. Inventory Inventory used in the retail pharmacy services segment consists of pharmaceuticals, which are carried at the lower of cost (first in, first out) or net realizable value. Inventory used in the pharmacy technology segment consists primarily of MedCenter kiosk units which are finished goods, as well as spare parts. Inventories are carried at the lower of cost (specific identification) or net realizable value. Impairment of Long Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable, the Company compares the carrying amount of an asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. For the years ended December 31, 2021 and 2020, the Company did not recognize any significant impairments of long lived assets. Property, plant and equipment Property, plant and equipment are carried at cost less accumulated depreciation and impairment. Gains and losses arising on the disposal of individual assets are recognized in income in the period of disposal. Costs, including financing charges and certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction-in-progress and are not subject to depreciation. Depreciation begins when an asset is placed into service on a straight-line basis over the estimated useful lives as follows: IT equipment 1 – 3 years General plant and equipment 5 – 8 years Vehicles 5 years Office furniture and equipment 5 – 8 years Leasehold improvements lesser of useful life or term of lease MedCenter equipment 8 years Maintenance and repairs are charged to expense as incurred. Renewals and betterments that materially prolong the useful lives of the assets are capitalized. The cost and related accumulated depreciation of property retired or sold are removed from the accounts, and gains or losses are recognized in the consolidated statements of operations. Intangible Assets Intangible assets consist of software, patents and know-how. Intangible assets acquired through asset acquisitions or business combinations are initially recognized at fair value based on an allocation of the purchase price. Software includes internal and external use software costs that are accounted for in accordance with ASC 350 and ASC 925, respectively. Costs associated with application development are capitalized as intangible assets. All other costs including planning, training, and conceptual evaluation are expensed. The intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization of the intellectual property commenced in 2014 on delivery of the first proof of concept MedCenter. The Company evaluates the reasonableness of the estimated useful lives of these intangible assets on an annual basis. Amortization is recorded from the date each asset is placed into service on a straight-line basis over the estimated useful lives of intangible assets as follows: Intellectual property 6 years Website and mobile application 2 years Software 1 – 5 years Leases The Company maintains operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, and certain equipment. ASC 842 requires lessees to recognize a right-of-use, or ROU, asset and a lease liability on the balance sheet for substantially all leases, except for short-term leases. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. New contracts are analyzed to determine whether they include leased assets; such leases are referred to as embedded leases. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicitly or implicitly identified asset in the contract and if the Company controls the use of that asset. The Company’s accounting policy treats leases with an initial term of 12 months or less as short-term leases. Lease expense for short-term lease payments are recognized on a straight-line basis over the term of the lease. Operating lease right-of-use, or ROU, assets and lease liabilities are recognized based on the present value of lease payments over the lease term. Because most of the leases do not include an implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments. As a practical expedient, the Company has elected not to separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs). As a result, if the non-lease components are fixed, they are included when calculating the ROU asset and related lease liability. See Note 12 for additional disclosures. Share-based compensation The Company has a stock compensation plan whereby awards are granted to certain employees. The fair value of the stock options and restricted stock units or RSUs granted by the Company to employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. The fair value of the options and RSU’s are measured using the Black-Scholes option pricing model and intrinsic value, respectively, as of the grant date date. Shares issued upon the exercise of options and vesting of RSUs are new shares. Forfeitures are estimated based on historical experience and expense related to awards, and the estimate is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are fully expensed. The Company has an employer stock purchase plan or ESPP, whereby employees may purchase a limited number of shares of the Company’s common stock. The fair value of the ESPP shares purchased by employees, as of the grant date, is recognized as compensation expense on a straight-line basis over the period from the grant date to the exercise date. Warrants The Company issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards once issued. Certain obligations to issue warrants as compensation for services may be initially classified as liabilities before the warrants are issued. The fair value of the awards are measured using the Black-Scholes option pricing model as of the grant date. Warrants issued on November 12, 2020 to a service provider were valued based on the liability settled with their issuance. Warrants issued are initially recorded at fair value as a reduction to additional paid in capital or as an expense if the warrants are issued to pay for services. Financing costs

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Dec. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Standards Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). This guidance removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU was effective beginning in the first quarter of our fiscal year 2021. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings(deficit) in the period of adoption. The Company assessed the impact of the new accounting standard on its consolidated financial statements to facilitate its required adoption of the new standard on January 1, 2021. The adoption of ASU 2019-12 did not result in a material change to our consolidated financial statements. Debt with Conversion and Other Options In August 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting For Convertible Instruments and Contracts in an Entity's Own Equity” (“ASU 2020-06”). The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per share calculation in certain areas. The Company assessed the impact of the new accounting standard on its consolidated financial statements to facilitate its early adoption of the new standard on January 1, 2021. As the Company has no outstanding convertible debt at the date of adoption, ASU 2020-06 did not impact our consolidated financial statements. Recently Issued Accounting Standards Not Yet Adopted Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, excluding smaller reporting companies. For all other entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding During the years ended December 31, 2021 and 2020, there was no potential dilution from stock options or other warrants due to the Company’s net loss position. Weighted average shares for historical periods have been adjusted for the effect of the 1.26 for 1 split on November 17, 2020 as part of the Merger. The following table sets forth the computation of basic and diluted earnings per share (in thousands, expect for share and per share amounts): Year Ended December 31, 2021 2020 Net loss - basic and diluted $ (43,815) $ (26,810) Weighted average shares - basic and diluted 32,656,325 5,722,095 Net loss per share - basic and diluted $ (1.34) $ (4.69)

FAIR VALUE MEASUREMENTS AND FIN

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS	FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS As of December 31, 2021 and 2020, our assets and liabilities that were accounted for at fair value were cash and cash equivalents, and restricted cash. Fair value measurements are categorized in one of the following three levels based on the lowest level input that is significant to the fair value measurement in its entirety: Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than quoted prices in active markets for identical assets or liabilities include: a. quoted prices for similar assets or liabilities in active markets; b. quoted prices for identical or similar assets or liabilities in inactive markets; c. inputs other than quoted prices that are observable for the asset or liability; d. inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3- Inputs to the valuation methodology are unobservable (i.e., supported by little or no market activity) and significant to the fair value measure. Assets and liabilities measured at fair value on a recurring basis were as follows (in thousands): Fair Value Hierarchy December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ — Fair Value Hierarchy December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 57,936 $ 57,936 $ — $ — Restricted cash 60 60 — — Total assets $ 57,996 $ 57,996 $ — $ — The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities, a Level 2 input. The carrying amount of the Company’s short-term notes and PPP loan approximated fair value due to their short-term nature and the loans carry a current market rate, a Level 2 input. The carrying amount of the Company's convertible promissory note approximated fair value based upon market interest rates available to us for debt of similar risk and maturities, a Level 2 input. Refer to Note 13, Debt, for further information regarding the Company’s term loan, short-term notes, PPP loan and convertible promissory note.

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	ACCOUNTS PAYABLE AND ACCRUED LIABILITIES The following table presents details of accounts payable and accrued liabilities (in thousands): December 31, 2021 2020 Accounts payable and accrued liabilities: Payroll $ 2,733 $ 2,760 Trade accounts payable 4,007 1,752 Total accounts payable and accrued liabilities $ 6,740 $ 4,512

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY The following table presents detail of inventory balances (in thousands): December 31, 2021 2020 Inventory: MedCenter hardware $ 1,201 $ 1,655 Pharmaceuticals 2,150 837 Spare parts 565 325 Total inventory $ 3,916 $ 2,817 During the years ended December 31, 2021 and 2020 the Company recorded inventory cost adjustments of $0.6 million and $0.2 million, respectively, that were included in pharmacy and hardware cost of products sold on the consolidated statement of operations and comprehensive loss. The inventory cost adjustments were specific to our M5 MedCenter kiosk model.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENTThe Company’s principal technology product offering is the MedCenter kiosk. MedCenter equipment includes the hardware and components necessary for installation and operation. The following tables present property, plant and equipment balances (in thousands): Estimated useful lives December 31, December 31, 2021 2020 Property, plant and equipment: MedCenter equipment 8 years $ 5,875 $ 4,622 IT equipment 1 - 3 years 2,361 1,999 Leasehold improvements lesser of useful life or term of lease 880 799 General plant and equipment 5 - 8 years 603 353 Office furniture and equipment 5 - 8 years 394 329 Vehicles 5 years 54 54 Construction-in-process 1,021 90 Total historical cost 11,188 8,246 Accumulated depreciation (5,496) (4,451) Total property, plant and equipment, net $ 5,692 $ 3,795 During the years ended December 31, 2021 and 2020, there was a transfer of $1.8 million and $1.5 million, respectively, from inventory to property, plant and equipment. MedCenter units in inventory are transferred to property, plant and equipment when those units are either placed at one of the Company’s SpotRx clinics or leased to a third party. As of December 31, 2021 and 2020, respectively, there was $1.7 million and $0.7 million of MedCenter equipment leased under Subscription Agreements, net of $1.0 million and $0.3 million accumulated depreciation, in property, plant and equipment. The Company recognized $1.2 million and $1.0 million of depreciation for the years ended December 31, 2021 and 2020, respectively, of which $0.2 million and $0.2 million, respectively, was included in pharmacy and hardware cost of products sold.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	- INTANGIBLE ASSETS The following table presents intangible asset balances (in thousands): December 31, 2021 2020 Gross intangible assets: Software $ 4,475 $ 1,815 Intellectual property 3,857 3,857 Website and mobile application 583 583 Total intangible assets 8,915 6,255 Accumulated amortization: Software (2,175) (1,588) Intellectual property (3,857) (3,857) Website and mobile application (583) (583) Total accumulated amortization (6,615) (6,028) Total net book value $ 2,300 $ 227 The Company recognized $0.6 million and $0.1 million of amortization for the years ended December 31, 2021 and 2020, respectively, which was included in operating expenses. Amortization expense for the intangible assets is expected to be as follows over the next five years, and thereafter (in thousands): December 31, 2021 2022 $ 413 2023 289 2024 282 2025 278 2026 122 Thereafter — Work-in-process 916 Total estimated amortization expense $ 2,300

LEASES

LEASES	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
LEASES	LEASES The Company maintains operating leases primarily for central pharmacies, corporate offices, research and development facilities, and certain equipment. Lease terms include options to extend or terminate leases when it is reasonably certain that the Company will exercise those options. Real estate leases for facilities have a remaining lease term of 1 – 5 years. Certain of the lease agreements contain variable lease payments that are adjusted periodically to adjust estimated amounts for actual operating expenses; these variable amounts are not material. When sublease income is generated for certain properties, MedAvail records its liability separately from those expected inflows. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. Operating lease expense was $0.9 million and $0.8 million for the years ended December 31, 2021 and 2020, respectively. Balance sheet amounts for lease assets and leases liabilities are as follows (in thousands): December 31, 2021 2020 Assets Operating: $ 2,376 $ 1,108 Finance: 162 131 Total assets $ 2,538 $ 1,239 Liabilities: Operating: Current 599 612 Long-term 1,947 572 Finance: Current 83 53 Long-term 80 79 Total liabilities $ 2,709 $ 1,316 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: December 31, 2021 2020 Finance leases: Weighted-average remaining lease term (years) 1.5 2.4 Weighted-average discount rate 8.8 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 4.2 2.5 Weighted-average discount rate 6.9 % 6.0 % Maturities of operating lease liabilities are as follows (in thousands): December 31, 2021 2022 $ 773 2023 714 2024 562 2025 478 2026 410 Thereafter 24 Total lease payments 2,961 Less: present value discount (415) Total leases $ 2,546 Maturities of finance lease liabilities are as follows (in thousands): December 31, 2021 2022 $ 93 2023 65 2024 22 2025 — 2026 — Thereafter — Total finance lease payments 180 Less: imputed interest (17) Total leases $ 163
LEASES	LEASES The Company maintains operating leases primarily for central pharmacies, corporate offices, research and development facilities, and certain equipment. Lease terms include options to extend or terminate leases when it is reasonably certain that the Company will exercise those options. Real estate leases for facilities have a remaining lease term of 1 – 5 years. Certain of the lease agreements contain variable lease payments that are adjusted periodically to adjust estimated amounts for actual operating expenses; these variable amounts are not material. When sublease income is generated for certain properties, MedAvail records its liability separately from those expected inflows. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. Operating lease expense was $0.9 million and $0.8 million for the years ended December 31, 2021 and 2020, respectively. Balance sheet amounts for lease assets and leases liabilities are as follows (in thousands): December 31, 2021 2020 Assets Operating: $ 2,376 $ 1,108 Finance: 162 131 Total assets $ 2,538 $ 1,239 Liabilities: Operating: Current 599 612 Long-term 1,947 572 Finance: Current 83 53 Long-term 80 79 Total liabilities $ 2,709 $ 1,316 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: December 31, 2021 2020 Finance leases: Weighted-average remaining lease term (years) 1.5 2.4 Weighted-average discount rate 8.8 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 4.2 2.5 Weighted-average discount rate 6.9 % 6.0 % Maturities of operating lease liabilities are as follows (in thousands): December 31, 2021 2022 $ 773 2023 714 2024 562 2025 478 2026 410 Thereafter 24 Total lease payments 2,961 Less: present value discount (415) Total leases $ 2,546 Maturities of finance lease liabilities are as follows (in thousands): December 31, 2021 2022 $ 93 2023 65 2024 22 2025 — 2026 — Thereafter — Total finance lease payments 180 Less: imputed interest (17) Total leases $ 163

DEBT

DEBT	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
DEBT	DEBT The following table presents debt balances (in thousands): December 31, 2021 2020 Term loan $ 10,070 $ — Term loan discount (532) — Convertible promissory note due March 2021 — — Short-term note due May 2021 — 1,000 Short-term note due November 2021 — 1,000 PPP loan — 161 Total debt 9,538 2,161 Less Short-term debt — 2,161 Long-term debt $ 9,538 $ — Term Loan On June 7, 2021, the Company entered into a Loan and Security Agreement, or the Loan Agreement, with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., pursuant to which we borrowed $10.0 million in aggregate initial term loans, or the Initial Loans. The Company may borrow up to an additional $20.0 million in aggregate term loans (or, together with the Initial Loans, the Loans) on or before April 30, 2022, subject to no material adverse change or event of default (each as defined in the Loan Agreement) having occurred and continuing. The Loans and the Company's obligations under the Loan Agreement are guaranteed by certain of our subsidiaries and are secured by substantially all of the assets of the Company and its subsidiary guarantors. The Loans mature on April 1, 2026. Principal repayment will commence on May 1, 2024 in equal monthly installments of the outstanding Loan balance through the maturity date. The Loans bear interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (7.25% at December 31, 2021). The Company may elect to prepay the Loans, in whole but not in part, at any time. If the Company elects to voluntarily prepay the Loans before the scheduled maturity date, the Company is required to pay the lenders a prepayment premium, equal to 3.0% of the outstanding principal balance if the prepayment occurs on or before June 7, 2022, 2.0% of the outstanding principal balance if the prepayment occurs on or before June 7, 2023, or 1.0% for a prepayment made after June 7, 2023, but before the scheduled maturity date. A prepayment premium is also applicable to a mandatory prepayment of the Loans upon an acceleration of the Loans. Upon a voluntary or mandatory prepayment of the Loans, the Company is also required to pay the lenders’ expenses and all accrued but unpaid interest on the Loans through the prepayment date. A final payment fee equal to 4.75% of the original principal amount of the Loans advanced will be due at the earlier of the maturity date, acceleration of the Loans, or a voluntary or mandatory prepayment of the Loans. The final payment fee is accreted to the Loan balance over the loan term using the effective interest method. The Loan Agreement includes customary representations and covenants that, subject to exceptions and qualifications, restrict the Company's ability to do the following things: engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; engage in businesses that are not related to existing business; add or change business locations; incur additional indebtedness; incur additional liens; make loans and investments; declare dividends or redeem or repurchase equity interests; and make certain amendments or payments in respect of any subordinated debt. In addition, the Loan Agreement contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, maintenance of our bank accounts, protection of our intellectual property, reporting requirements, compliance with applicable laws and regulations, and formation or acquisition of new subsidiaries. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and payable and may exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include, subject to grace periods in certain instances, payment defaults, breaches of covenants or representations and warranties, a material adverse change as defined in the Loan Agreement and with respect to certain governmental approvals, material judgments and attachments, cross defaults with certain other material indebtedness, bankruptcy and insolvency events with respect to the Company and its subsidiaries, and delisting of the Company's shares from NASDAQ. Loan issuance costs of $0.6 million are included in long term debt and are amortized to interest expense over the loan term using the effective interest method. Convertible Promissory Note due March 2021 On March 24, 2016, the Company and a significant customer and investor entered into a subordinated secured convertible promissory five-year note agreement for $10.0 million. This note was convertible into common shares at the option holder’s request. Additionally, upon a change of control event as defined in the note agreement or upon an Initial Public Offering, or IPO, as defined under the agreement, the option holder could request conversion of the note into Series D preferred stock at $91.02 per share. Interest of 6% was accumulated and repayable on the maturity date at the Company’s option. Unpaid interest was added to the outstanding principal. This note, including accrued interest, was repaid in its entirety on November 17, 2020 with proceeds from the offering. Note Offering On May 26, 2020, the Company completed a convertible notes and warrants offering, or 2020 Note and Warrant Purchase Agreement, to certain of its existing investors whereby those investors purchased notes and warrants on a pro rata basis with their existing investments in the Company’s preferred stock. On September 29, 2020, a First Amendment to the 2020 Note and Warrant Purchase Agreement was entered into that extended the maturity date and indicated an aggregate principal amount limit. Cash received for the notes and warrants was $12.7 million (including $8.5 million from related parties). The notes accrued interest at a rate of 10%, payable at maturity or upon conversion with a maturity date of June 30, 2021. As part of the Merger, principal and interest amounts of $13.1 million were converted to common stock, pursuant to the agreement. See Note 19 for further information. PPP Loan On May 14, 2020, the Company entered into two Promissory Notes with HSBC Bank, which provided for a loan in the aggregate amount of $0.3 million, or the PPP Loan, pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. The PPP Loan had a two-year term and an interest at a rate of 1.0% per annum. Monthly principal and interest payments were deferred for six months after the date of disbursement. The PPP Loan could have been prepaid at any time prior to maturity with no prepayment penalties. The Promissory Note contained events of default and other provisions customary for a loan of this type. The Paycheck Protection Program provided that the PPP Loan may be partially or wholly forgiven if the funds are used for certain qualifying expenses, including certain payroll costs, group health care benefits and other permitted expenses as described in the CARES Act. During 2020, the Company used the entire PPP Loan amount for qualifying expenses. The Company applied for forgiveness of the loan in accordance with the terms of the CARES Act. During March 2021 and November 2020, the Company received notice that $0.1 million and $0.2 million, respectively, of the loan was forgiven. Upon forgiveness of the PPP loan, the PPP loan amount was treated as a government grant. MYOS Promissory Note

PHARMACY OPERATIONS EXPENSES

PHARMACY OPERATIONS EXPENSES	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
PHARMACY OPERATIONS EXPENSES	PHARMACY OPERATIONS EXPENSES Pharmacy operations expenses are as follows (in thousands): Year Ended December 31, 2021 2020 Pharmacy operations expenses: Wages and salaries $ 9,844 $ 4,486 Other pharmacy operations expenses 1,374 612 Depreciation of property, plant and equipment 826 655 Rent and utilities 558 275 Repairs and maintenance 316 97 Amortization of intangible assets 578 21 Total pharmacy operations expenses $ 13,496 $ 6,146

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
GENERAL AND AMINISTRATIVE EXPENSES	GENERAL AND ADMINISTRATIVE EXPENSES General and administrative expenses are as follows (in thousands): Year Ended December 31, 2021 2020 General and administrative expenses: Wages and salaries $ 10,980 $ 9,682 Professional services 3,457 2,001 Insurance 1,780 503 Rent and utilities 1,338 1,242 Other general and administrative expenses 1,021 669 Share-based compensation 1,205 380 Software licenses and support 1,179 419 Travel and other employee expenses 736 359 Office and IT supplies 393 441 Depreciation of property, plant and equipment 188 167 Total general and administrative expenses $ 22,277 $ 15,863

OTHER GAIN (LOSS)

OTHER GAIN (LOSS)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
OTHER GAIN (LOSS)	OTHER GAIN (LOSS) Other gain (loss) is as follows (in thousands): Year Ended December 31, 2021 2020 Other gain (loss), net Forgiveness of PPP Loan $ 161 $ 181 Other gain (loss), net 45 (291) Total other gain (loss), net $ 206 $ (110)

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The provision for income taxes in the consolidated statement of operations and comprehensive loss represents an effective rate different from the US statutory tax rate for the following reasons (in thousands): Year Ended December 31, 2021 2020 Loss before income taxes $ (43,813) $ (26,810) Income tax recovery at statutory rate (21%) (9,201) (5,630) State income tax expense, net of federal benefit (1,955) — Increase resulting from: Effect of foreign tax rate (610) (252) Unrecognized deferred tax asset 14,356 5,642 Permanent and other differences (2,588) 240 Provision for income taxes $ 2 $ — On March 11, 2021, the U.S. federal government enacted the American Rescue Plan Act of 2021, which did not have a material impact on our provision. The effects of temporary differences that give rise to future income tax assets and future income tax liabilities have been determined as follows (in thousands): Year Ended December 31, 2021 2020 Future income tax assets: Non-capital losses $ 44,590 $ 31,658 Un-depreciated capital cost (UCC) 1,525 1,868 Other intangible items 1,556 223 Interest limitation carryforward 463 — Total future income tax assets 48,134 33,749 Future income tax liabilities: Unrecognized deferred tax asset (48,134) (33,749) Net future income tax asset $ — $ — The Company is required to reduce its deferred tax assets by a valuation allowance if it is more likely than not that some or all of its deferred tax assets will not be realized. Management must use judgment in assessing the potential need for a valuation allowance, which requires an evaluation of both negative and positive evidence. The weight given to the potential effect of negative and positive evidence should be commensurate with the extent to which it can be objectively verified. In determining the need for and amount of the valuation allowance, if any, the Company assesses the likelihood that it will be able to recover its deferred tax assets using historical levels of income, estimates of future income and tax planning strategies. As a result of historical cumulative losses, the Company determined that, based on all available evidence, there was substantial uncertainty as to whether it will recover recorded net deferred taxes in future periods. Accordingly, the Company recorded a valuation allowance against all of its net deferred tax assets as of December 31, 2021 and 2020. The net valuation allowance increased by $14.4 million in 2021. As of December 31, 2021, the Company has federal net operating loss carryforwards of approximately $62.8 million, of which $11.6 million will begin to expire in the year 2032 if not utilized, and $51.2 million that will carryover indefinitely. In addition, the Company has approximately $103.8 million of non-capital losses in Canada that can be used to reduce taxable income in future years. These losses will begin to expire in the year 2032. Utilization of the Company’s net operating loss or NOL carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“Section 382”) as well as similar state provisions. These ownership changes may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to significant complexity with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforward would be subject to an annual limitation under Section 382. Although the Company has not completed its analysis, it is reasonably possible that its federal NOLs available to offset future taxable income could materially decrease. This reduction would be offset by an equal and offsetting adjustment to the existing valuation allowance. Given the offsetting adjustments to the existing valuation allowance, any ownership change is not expected to have an adverse material effect on the Company’s consolidated financial statements. Any limitation may result in expiration of a portion of the net operating loss carryforward before utilization. The Company has filed all income tax returns for years through 2020. These returns are subject to examination by the taxing authorities in the respective jurisdictions, generally for three or four years after they were filed. Based on an analysis of tax positions taken on income tax returns filed, we determined no material liabilities related to uncertain income tax positions existed as of December 31, 2021 or 2020. Although we believe the amounts reflected in our tax returns substantially comply with applicable U.S. federal, state and foreign tax regulations, the respective taxing authorities may take contrary positions based on their interpretation of the law. A tax position successfully challenged by a taxing authority could result in an adjustment to our benefit for income taxes in the period in which a final determination is made. A reconciliation of the beginning and ending amounts of unrecognized deferred tax benefits is as follows (in thousands): Year Ended December 31, 2021 2020 Beginning balance $ 33,749 $ 27,672 Additions based on tax positions related to the current year 14,385 6,077 Ending balance $ 48,134 $ 33,749 The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefit as a component of income tax expense. The Company does not expect any significant changes to the unrecognized tax benefits within the next 12 months.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Following MYOS Rens Technology Inc.’s, or MYOS, and MedAvail, Inc.’s, or MAI, announcement of the execution of the Agreement and Plan of Merger and Reorganization dated June 30, 2020, or the Merger Agreement, on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, or collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation. The Demands and the Complaints that comprise the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MAI aided and abetted such breach of fiduciary duties. MYOS and MAI believe that the claims asserted in the Litigation are without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the transactions contemplated by the Merger Agreement, or the Merger, and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. The remainder of the Litigation remains outstanding. MYOS and MedAvail specifically deny all allegations in the Litigation and/or that any additional disclosure was or is required. Purchase Commitments As of December 31, 2021 and 2020, the Company did not have any minimum purchase commitments that were material to the consolidated financial statements. Defined Benefit Plans MedAvail has a 401(k) plan available to employees, but during 2021 and 2020, had no commitment to make contributions to that plan and had no liability recorded related to the plan. Revenue Concentration Risk The Company partners with various national and independent healthcare organizations where the SpotRx MedCenters are located. Revenue from the MedCenters placed with healthcare organization A and B comprised 25% and 14%, respectively, of total revenue for the year ended December 31, 2021. Disruption of these relationships could have a significant impact on the Company. In September 2020, the Company and a significant customer agreed that MedAvail had no further obligation to the customer and therefore would have no additional deliverables related to the contract liability balance, of which $4.7 million was outstanding as of December 31, 2019. As such, the Company recognized $1.5 million of hardware revenue and $3.2 million of service revenue related to this contract during 2020, which was 34% of total revenue for the year ended December 31, 2020. Accounts Receivable Concentration Risk Three Pharmacy Retail Services segment payors accounted for 61% of accounts receivable at December 31, 2021; and two payors accounted for 37% of accounts receivable at December 31, 2020. Disruption of these relationships could have a significant impact on the Company. Vendor Concentration Risk The following table presents the Company’s vendor concentration: Year Ended December 31, 2021 2020 Vendor A 32 % 26 % Vendor B — % 15 % Vendor C 12 % — % Vendor A and C are significant inventory suppliers and disruption of the relationships could have a significant impact on the Company. Vendor B was engaged for a one time project during 2020. The Company relies on one vendor to manufacture MedCenters, which makes the Company vulnerable to supply shortages and price fluctuations that could have a material adverse effect on the business, financial condition and results of operations. Additionally, disruption of this relationships could have a significant impact on the Company.

REDEEMABLE PREFERRED STOCK, DEF

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE	REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE Redeemable Preferred Shares Prior to the Merger, the outstanding MAI preferred stock was redeemable at the option of the holder, but not mandatorily redeemable, therefore it was classified as mezzanine equity and was recognized at the fair value as of the date of issuance (the proceeds on the date of issuance). The following table presents changes in preferred shares outstanding (in thousands, except share amounts): Preferred Shares Shares Amount Balance at December 31, 2019 10,500,440 $ 93,484 Issued 102,777 788 Converted to common shares in Merger (10,603,217) (94,272) Balance at December 31, 2020 — $ — There was no redeemable preferred stock activity in 2021. MAI had 10,000,000 authorized preferred shares, with a normal or par value of $0.001 per share. Pursuant to the terms of the Series E financing agreement, if a shareholder elected to participate in the financing, they were granted a number of conversion shares that were exchanged into the number of shares of such series of preferred stock equal to the number of shares held by such shareholder immediately prior to the common share conversion. Additionally, Series C, Series D and Series E preferred shares were subject to a full-ratchet anti-dilution adjustment until the earlier of the three-year anniversary of the initial Series E issuance date or the first equity financing at a price greater than the Series E original purchase price, with aggregate gross proceeds of greater than $10.0 million. The final closing of the first tranche of the Series E financing round occurred in June 2018, with additional tranches occurring in March, July and December 2019. On November 17, 2020, all shares of preferred stock were converted to common shares as follows: Shares Before Conversion Conversion Ratio Common Shares Issued Series A preferred stock 1,175,544 1.00 1,175,544 Series B preferred stock 2,222,886 1.00 2,222,886 Series C preferred stock 1,634,249 1.54 2,517,665 Series D preferred stock 502,630 1.62 813,050 Series E preferred stock 5,067,908 1.00 5,067,910 Total 10,603,217 11,797,055 No preferred shares were outstanding at December 31, 2021 and 2020. Voting The holders of the Preferred Stock were entitled to vote, together with the holders of common stock, on certain matters, exclusive of certain protective provisions under the Amended and Restated Certificate of Incorporation, or the Protective Provisions, submitted to stockholders for a vote. Each preferred stockholder was entitled to the number of votes equal to the number of shares of common stock into which each preferred share is convertible at the time of such vote. The holders of the Preferred Stock voted, as a single class on an as converted to common stock basis, separately from the holders of common stock and subject to a 60% affirmative vote, on certain Protective Provisions, including but not limited to: entering into any liquidation event, merger, consolidation or form of reorganization; modifying the rights and privileges of the Preferred Stock so as to adversely affect the Preferred Stock; declaring or paying any dividend; redeeming, repurchasing or otherwise acquiring shares of common stock; amending the Certificate of Incorporation or By-Laws of the Company; increasing the number of authorized shares of Preferred Stock or common stock; and revising the number of members of the of Board of Directors. Dividends The holders of Preferred Stock were entitled to receive dividends, when and if declared by the Board of Directors and out of funds legally available. If a dividend was paid on the common shares, preferred shareholders would have been paid the same per-share dividend amount on an as-if-converted to common basis. Through November 18, 2020 MAI had not declared or paid any dividends. The annual dividend rate by series is as follows: Series A $ 0.41 CAD Series B $ 0.57 CAD Series C $ 1.36 CAD Series D $ 1.42 CAD Series E $ 0.88 CAD Liquidation In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of MAI, the holders of the Preferred Stock, would have received a certain amount per share plus all declared but unpaid dividends, payable in preference and priority to any payments made to the holders of the common stock. The Holders of preferred shares would have been paid in accordance with the following liquidation preference with each series having the right to be paid before the others. Series E, Series D, Series C, Series B, Series A. The amount received per share is as follows: Series A $ 5.13 CAD Series B $ 7.10 CAD Series C $ 16.95 CAD Series D $ 17.79 CAD Series E $ 11.00 CAD If preferred shareholders would have received a greater payment had their shares been converted to common shares prior to the liquidation, they would instead receive that greater amount. All remaining assets would have been paid to holders of common shares pro rata based on the number of shares held. Conversion Each share of Preferred Stock was convertible at the option of the holders at any time after the date of issuance into a number of shares of common stock as determined by dividing the conversion rate for that series of preferred shares by the conversion price in effect at the time of conversion, adjustable for certain dilutive events. All preferred shares would have automatically converted into common shares (i) on the closing of an IPO that generates at least $30.0 million CAD (net of underwriting discount and commissions) in proceeds to MAI; or (ii) on the election to do so by holders of at least two-thirds of the then outstanding preferred shares, voting on an as-if-converted to common basis. Common stock issued upon conversion are new shares. Conversion rates are as follows: Series A $ 5.13 CAD Series B $ 7.10 CAD Series C $ 11.00 CAD Series D $ 11.00 CAD Series E $ 11.00 CAD Redemption On or after December 19, 2025, on the request of holders of at least 60% of the then outstanding preferred shares, on an as-converted basis, MAI would have redeemed all preferred shares at the original issue price per share plus all accrued and declared but unpaid dividends. Payment would have been in three equal annual installments. The redemption would have been effected in accordance with the liquidation preferences. Common shares MAI had 100,000,000 authorized common shares, with a nominal or par value of $0.001 per share. In connection with the initial closing of the Series E preferred share financing that occurred on December 20, 2017, each series of MAI’s outstanding preferred shares were converted into common shares. The Company then effected a 7 to 1 reverse stock split on the common shares. In connection with the Merger transaction described in Note 1, each series of MAI’s outstanding preferred shares were converted into the Company’s common shares as described above. The Company then effected a 1.26 to 1 stock split on the common shares. All references in the consolidated financial statements to the number of shares outstanding and stock option data of the Company’s common stock have been restated to reflect the effect of the stock splits for all periods presented. Liquidation Rights In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for all series of outstanding redeemable convertible preferred stock. Dividend and Voting Rights The holders of common stock are entitled to receive dividends if and when declared by the Board of Directors of the Company, but not until all dividends on redeemable convertible preferred stock have been either (i) paid or (ii) declared and the Company has set aside funds to pay those dividends declared. Holders of common stock have the right to one vote per share. Share-based compensation Update for Merger Pursuant to the Merger Agreement, effective as of the Effective Time of the Merger, the Company assumed the 2018 MedAvail Equity Incentive Plan, or the 2018 Plan, and the 2012 MedAvail Stock Option Plan, or the 2012 Plan, assuming all of MAI’s rights and obligations with respect to the options issued thereunder. Immediately thereafter, the Company terminated the 2018 Plan. The 2012 Plan was previously modified on the date the 2018 Plan was adopted to no longer permit granting of options under the 2012 Plan. Pursuant to the Merger Agreement, at the Effective Time of the Merger, the Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, and the 2020 Employee Stock Purchase Plan, or the 2020 ESPP. The 2018 Plan was closed to granting of options upon adoption of the 2020 Plan. 2020 Plan The 2020 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, or the Code, to the Company’s employees and any parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants of the Company and the company group. The number of shares of Company Common Stock that are reserved for issuance pursuant to awards under the 2020 Plan at inception was 5,000,000 shares (post-Reverse Stock Split). The 2020 Plan also includes an evergreen provision that provides for an automatic annual increase to the number of shares of common stock available for issuance under the 2020 Plan on the first day of each fiscal year, equal to the least of: (i) 5,000,000 shares; (ii) 5% of the total number of shares of all classes of common stock of the Company as of the last day of our immediately preceding fiscal year; or (iii) such lesser amount determined by the administrator. As of December 31, 2021 there was an aggregate of 3.4 million shares of common stock available for grant under the 2020 Plan. The 2020 Plan will terminate on the tenth anniversary of its effective date. No award may be made under the 2020 Plan after its expiration date. 2020 ESPP The 2020 ESPP provides eligible employees with an opportunity to purchase shares of the Company’s Common Stock through accumulated contributions, which generally will be made through payroll deductions. The 2020 ESPP permits the administrator of the 2020 ESPP to grant purchase rights that qualify for preferential tax treatment under Section 423 of the Code. The maximum number of shares of our common stock that will be available for issuance under the 2020 ESPP at inception was 700,000 shares (post-Reverse Stock Split). The number of shares of common stock available for issuance under the 2020 ESPP Plan will be increased on the first day of each fiscal year beginning with the 2021 fiscal year equal to the least of (i) 1,000,000 shares of common stock; (ii) one percent 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year; or (iii) an amount determined by the administrator. The shares may be authorized, but unissued, or reacquired common stock. As of December 31, 2021 there was an aggregate of 1.0 million shares of common stock, available for grant under the 2020 ESPP. During the year ended December 31, 2021, eligible employees contributed $0.1 million through payroll deductions to the ESPP and 42,739 shares were deemed delivered. The 2020 ESPP will terminate in 2040, unless terminated sooner. 2018 Plan In September 2018, MAI adopted the 2018 MedAvail Equity Incentive Plan, or the 2018 Plan, which provided for the granting of stock options to service providers of MAI. As part of the adoption of the 2018 Plan, MAI provided the option for all eligible service providers to exchange their options held under the 2012 MedAvail Stock Option Plan, or the 2012 Plan, as of the exchange date for new options under the 2018 Plan, at an exchange ratio of 1:5. All vesting schedules were maintained on exchange. A total of 53 eligible service providers participated in the exchange, which resulted in the exchange of 239,181 options under the 2012 Plan for 1,269,180 options under the 2018 Plan. The exchange resulted in $1.0 million of one-time incremental compensation cost for 2018. The 2018 Plan was closed to granting options upon adoption of the 2020 Plan. 2012 Plan The 2012 MedAvail Stock Option Plan was modified on the date the 2018 Plan was adopted to no longer permit granting of options under the plan. As of December 31, 2021, there are 5,777 options that remained outstanding under this plan. Options granted under the 2012 Plan that were not exchanged to options under the 2018 Plan will remain subject to the terms of the 2012 Plan. Grants The maximum number of shares to be granted under the 2018 plan was 1,972,530. In accordance with the plan, the exercise price of each option is based on the fair value of MAI’s common shares on the date of the grant. An option’s term was determined at the discretion of the Board of Directors, not to exceed ten years. Unless otherwise stated, the consolidated financial statements reflect 1/48 of the option vesting each month over a four-year vesting period. During 2021, the Company granted 1,003,130 new options at a weighted average exercise price of $6.07, and 852,395 RSUs to employees. The estimated fair value of the options and RSUs was determined by the Black-Scholes valuation model and intrinsic value, respectively. During 2020, MAI granted 442,830 new options to service providers at a weighted average exercise price of $1.34. The estimated fair value of the options was determined by the Black-Scholes valuation model. The key input assumptions that were utilized in the valuation of the stock options granted in the periods presented are as follows: December 31, 2021 Low Weighted Average High Total Awards Granted 1,003,130 Weighted Average Fair Value of Awards $ 3.32 Unvested Forfeiture Rate 6.00 % 6.00 % 6.00 % Grant Price $ 1.70 $ 6.07 $ 15.15 Market Price $ 1.70 $ 6.07 $ 15.15 Volatility 60 % 60 % 60 % Risk Free Rate 0.46 % 1.12 % 1.36 % Dividend Yield — % — % — % Expected Life 5.17 5.94 6 December 31, 2020 Low Weighted Average High Total Awards Granted 442,830 Weighted Average Fair Value of Awards $ 0.72 Unvested Forfeiture Rate 6.00 % 6.00 % 6.00 % Grant Price $ 1.34 $ 1.34 $ 1.34 Market Price $ 1.34 $ 1.34 $ 1.34 Volatility 60 % 60 % 60 % Risk Free Rate 0.43 % 0.43 % 0.44 % Dividend Yield — % — % — % Expected Life 5.87 5.92 6.02 The key input assumptions that were utilized in the valuation of the RSUs granted in the periods presented are as follows: December 31, 2021 Low Weighted Average High Total Awards Granted 852,395 Weighted Average Fair Value of Awards $ 3.35 Unvested Forfeiture Rate 6.00 % 6.00 % 6.00 % Grant Price $ — $ — $ — Market Price $ 1.70 $ 3.35 $ 15.15 The following table present outstanding stock option awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding, beginning of period 2,439,020 $ 1.56 $ 0.76 $ 32,894 Granted 1,003,130 $ 6.07 $ 3.32 $ — Exercised (237,330) $ 1.67 $ 9.90 $ 0.81 $ 1,954 Cancelled/Forfeited (335,971) $ 4.75 $ 2.58 $ 392 Expired (19,946) $ 1.65 $ 0.77 $ 20 Outstanding, end of period 2,848,903 $ 2.78 $ 1.44 7.61 $ 31 Vested and exercisable, end of the period 1,834,645 $ 1.95 $ 0.95 6.64 $ 24 Vested and unvested exercisable, end of the period 1,834,645 $ 1.95 $ 0.95 6.64 $ 24 Vested and expected to vest, end of the period 2,754,222 $ 2.74 $ 1.42 7.55 $ 31 The following table present unvested stock option awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Amortization Period (Years) Unvested outstanding, beginning of period 693,644 $ 1.40 $ 0.69 Granted 1,003,130 $ 6.07 $ 3.32 Cancelled/Forfeited (333,565) $ 4.77 $ 2.59 Expired (19,946) $ 1.65 $ 0.77 Vested, outstanding shares (329,005) $ 3.36 $ 1.71 Unvested outstanding, end of period 1,014,258 $ 4.28 $ 2.34 3.11 The following table present the outstanding stock option awards activity during the year ended December 31, 2020: Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding, beginning of period 2,391,401 $ 1.59 $ 0.76 $ — Granted 442,830 $ 1.34 $ 0.72 $ 4,960 Exercised (160,090) $ 1.84 $ 11.09 $ 0.98 $ 1,482 Cancelled/Forfeited (235,121) $ 1.63 $ 0.76 $ 2,886 Outstanding, end of period 2,439,020 $ 1.56 $ 0.76 8.2 $ 32,894 Vested and exercisable, end of the period 1,745,376 $ 1.63 $ 0.78 7.9 $ 23,428 Vested and unvested exercisable, end of the period 1,745,376 $ 1.63 $ 0.78 7.9 $ 23,428 Vested and expected to vest, end of the period 2,386,417 $ 1.57 $ 0.76 8.2 $ 32,175 The following table presents unvested stock option awards activity during the year ended December 31, 2020: Number of Awards Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Amortization Period (Years) Unvested Outstanding, beginning of period 712,559 $ 1.44 $ 0.68 Granted 442,830 $ 1.34 $ 0.72 Cancelled/Forfeited (18,481) $ 1.54 $ 0.76 Vested, outstanding shares (443,264) $ 1.44 $ 0.72 Unvested Outstanding, end of period 693,644 $ 1.40 $ 0.69 2.5 The following table present outstanding RSU awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding, beginning of period — $ — $ — Granted 852,395 $ 3.35 $ 2,858 Exercised (11,155) $ 1.93 $ 11.58 $ 22 Cancelled/Forfeited (38,500) $ 12.83 $ 138 Outstanding, end of period 802,740 $ 2.78 $ 1,124 Vested and exercisable, end of the period — $ — $ — Vested and unvested exercisable, end of the period — $ — $ — Vested and expected to vest, end of the period 717,476 $ 2.81 4.9 $ 1,005 The following table present unvested RSU awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Grant Date Fair Value Weighted Average Remaining Amortization Period (Years) Unvested outstanding, beginning of period — $ — Granted 852,395 $ 3.35 Cancelled/Forfeited (38,500) $ 12.83 Vested, outstanding shares (11,155) $ 11.58 Unvested outstanding, end of period 802,740 $ 2.78 2.7 The following table presents expense related to share-based compensation: Year Ended December 31, 2021 2020 Share-based compensation $ 1,205 $ 380 Share-based compensation expense includes $0.1 million and zero from the ESPP for the years ended December 31 2021 and 2020, respectively. Expense remaining to be recognized for unvested stock option and RSU awards as of December 31, 2021 was $3.6 million, which will be recognized on a weighted average basis over the next 3 years. The aggregate fair value of stock options and RSUs vested during 2021 and 2020 was $1.2 million and $0.3 million, respectively. The Company has not recognized an income tax benefit in its income tax provision due to the full reserve against net operating losses and tax assets, see Note 17 for additional details. During the period from January 1, 2022, to March 29, 2022, the Company awarded 1.7 million stock options to employees with exercise prices ranging from $0.83 to $1.38 per share with a total fair value of $1.5 million, and issued 1.2 million RSUs to employees with a total fair value of $1.4 million. Warrants During the year ended December 31, 2021, no warrants were issued, and warrants were exercised in exchange for issuing 794,804 shares of the Company’s common stock with total cash proceeds of $0.2 million. Warrants exercised during the year ended December 31, 2021, included 565,496 held by related parties (investors), with 626,339 related party warrants outstanding as of December 31, 2021. During the year ended December 31, 2020 warrants issued were as follows: Year Ended December 31, 2020 Issue Date Reason for issuance Amount Term (years) Exercise Price 2/11/2020 Equity offering 27,427 10.0 $ 1.57 2/11/2020 Payment for services 309,698 10.0 $ 0.01 2/19/2020 Payment for services 6,855 10.0 $ 1.57 5/26/2020 Issuance of promissory note 115,374 0.5 $ 1.57 6/4/2020 Payment for services 16,119 10.0 $ 1.57 6/9/2020 Issuance of promissory note 1,676 0.5 $ 1.57 6/10/2020 Issuance of promissory note 761 0.5 $ 1.57 6/17/2020 Issuance of promissory note 319 0.5 $ 1.57 6/29/2020 Payment for services 84,911 10.0 $ 0.01 7/2/2020 Bridge financing 2,285 10.0 $ 1.57 8/14/2020 Bridge financing 1,524 10.0 $ 1.57 8/21/2020 Bridge financing 2,285 10.0 $ 1.57 10/2/2020 Bridge financing 6,857 10.0 $ 1.57 10/6/2020 Bridge financing 61,331 10.0 $ 1.57 10/7/2020 Bridge financing 381 10.0 $ 1.57 11/12/2020 Option cancellation 201,648 8.0 $ 1.57 11/18/2020 Payment for services 58,518 5.0 $ 0.01 At the end of the year, the Company had the following outstanding warrants: December 31, 2021 December 31, 2020 Warrants Exercise price Term (years) Warrants Exercise price Term (years) Common 19,310 $ 0.01 571,355 $ 0.01 Common — $ 6.93 288,352 $ 6.93 Common 224,852 $ 1.66 260,250 $ 1.66 Common 493,173 $ 1.57 557,598 $ 1.57 Total 737,335 $ 1.56 7.6 1,677,555 $ 1.97 7.8 Additionally, the Company had agreements with a service provider that would require the Company to issue additional warrants if that service provider met its obligations and performance milestones under that agreement. The Company had no liability as of December 31, 2021 and 2020, for the expense related to the expected issuance of the warrants in the future.

REVENUE AND SEGMENT REPORTING

REVENUE AND SEGMENT REPORTING	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
REVENUE AND SEGMENT REPORTING	REVENUE AND SEGMENT REPORTINGOperating segments are the individual operations that the Chief Operating Decision Maker or CODM reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The pharmacy technology and retail pharmacy services operating segments both engage in different business activities from which they earn revenues and incur expenses. See Note 4 for additional discussion on revenue for the operating segments. The Company has the following two reportable segments: Retail Pharmacy Services Segment Retail Pharmacy Services Segment revenue consists of products sold directly to consumers at the point of sale. The Company recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts. Pharmacy Technology Segment The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform Systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. Agreements can be for a predetermined period of time, or indefinite. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services. In September 2020, the Company and a significant customer agreed that MedAvail had no further obligation to the customer and therefore would have no additional deliverables related to the contract liability balance, of which $4.7 million was outstanding as of December 31, 2019. As such, the Company recognized $4.7 million of revenue related to this contract during 2020. The contract revenue recognized consisted of $1.5 million of hardware revenue and $3.2 million of software integration for contract obligations for software programming and hardware development that were in progress but not completed. The following table presents revenue and costs of revenue by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Year Ended December 31, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 20,203 $ — $ 20,203 Hardware — 470 470 Subscription — 446 446 Total pharmacy and hardware revenue 20,203 916 21,119 Service revenue: Software integration — — — Software — 259 259 Maintenance and support — 161 161 Installation — 39 39 Professional services and other — 551 551 Total service revenue — 1,010 1,010 Total revenue 20,203 1,926 22,129 Cost of products sold and services 20,031 1,781 21,812 Segment gross profit $ 172 $ 145 317 Operating expense: Pharmacy operations 13,496 General and administrative 22,277 Selling and marketing 7,204 Research and development 849 Merger expenses — Total operating expense 43,826 Operating loss $ (43,509) Retail Pharmacy Services Pharmacy Technology Total Year Ended December 31, 2020 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 7,728 $ — $ 7,728 Hardware — 2,401 2,401 Subscription — 467 467 Total pharmacy and hardware revenue 7,728 2,868 10,596 Service revenue: Software integration — 3,168 3,168 Software — 44 44 Maintenance and support — 58 58 Installation — 55 55 Professional services and other — 47 47 Total service revenue — 3,372 3,372 Total revenue 7,728 6,240 13,968 Cost of products sold and services 7,744 1,061 8,805 Segment gross profit $ (16) $ 5,179 5,163 Operating expense: Pharmacy operations 6,146 General and administrative 15,863 Selling and marketing 3,283 Research and development 682 Merger expenses 4,691 Total operating expense 30,665 Operating loss $ (25,502) The following table presents assets and liabilities by segment (In thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 December 31, 2020 Assets $ 6,012 $ 5,547 $ 57,772 $ 69,331 Liabilities $ 2,203 $ 3,422 $ 2,639 $ 8,264 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): Year Ended December 31, 2021 2020 Long-lived assets: United States $ 7,675 $ 4,533 Canada $ 555 $ 501 Total long-lived assets $ 8,230 $ 5,034

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of all subsidiaries of the Company with intercompany transactions and balances eliminated on consolidation. All of the Company’s subsidiaries are wholly owned. These consolidated financial statements have been prepared by management in accordance with United States generally accepted accounting principles (“U.S. GAAP”) on a basis consistent for all periods presented. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, impairment of long-lived assets; and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are deemed to be necessary. Risks and Uncertainties relating to COVID-19 The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and known and unknown impacts of COVID-19 as of December 31, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the recoverability of the Company’s, PPE and intangible assets, net realizable value of inventory, and recoverability of right-of-use operating lease assets. As of the date of issuance of the financial statements, the Company is not aware of any additional events or circumstances which would require it to update its estimates, judgments, or revise the carrying value of its assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and such changes will be recognized in the consolidated financial statements as soon as they become known. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements. Fiscal years ended December 31, 2021 and December 31, 2020, respectively, may be referred to as 2021 and 2020. Amounts presented in these consolidated financial statements are in United States dollars unless otherwise indicated. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our accounting policies are set forth in Note 4. Significant Accounting Policies.
Principles of consolidation	Principles of consolidationThe consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. MedAvail Technologies Inc., MedAvail Technologies (US) Inc., MedAvail Pharmacy Inc., and MedAvail, Inc. are all subsidiaries of the Company. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company classifies all highly liquid instruments with an original maturity of three months or less as cash equivalents. The Company’s cash and cash equivalents generally include funds held in checking and savings accounts at large American and Canadian financial institutions and denominated in U.S. Dollars and Canadian Dollars.
Restricted Cash	Restricted Cash The Company considers cash to be restricted when withdrawal or general use is legally restricted. During 2020 the Company maintained a balance with the issuer of certain purchasing cards as a guarantee for those cards. During the year ended December 31, 2021, MedAvail recovered the prior $0.06 million restricted cash balance that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicone Valley Bank (See Note 13), MedAvail issued letters of credit to secure certain operating leases, and MedAvail is required to maintain a $0.40 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposits, the balances were classified as restricted cash. Restricted cash was included in the balance for cash presented in the statements of cash flows.
Accounts Receivable	Accounts Receivable Accounts receivable are primarily comprised of trade receivables presented net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts based on its assessment of the collectability of amounts owed by customers. The allowance consists of known specific troubled accounts as well as an amount based on overall estimated potential uncollectible accounts receivable based on historical experience. At December 31, 2021 and 2020, the allowance for doubtful accounts had a balance of $0.1 million and $0.0 million, respectively.
Prepaid expenses and other current assets	Prepaid expenses and other current assetsPrepaid expenses and other current assets consist primarily of prepaid amounts for insurance, rent and general operating expenses.
Research and Development	Research and DevelopmentResearch and development expenses represent costs incurred to internally develop and innovate the MedCenter platform technology, including research and development on the MedCenter kiosk hardware, and related software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs. The Company does not incur research and development for others or provided such services to external parties. When research and development costs are incurred to develop hardware, the costs are expensed until technological feasibility is achieved, at which point the costs are capitalized.
Software	Software Software development costs are accrued and expensed based on ASC 985 or ASC 350 for external and internal use software, respectively. External use software includes software costs for applications that the Company intends to sell or lease (in conjunction with related hardware). Internal use software includes software costs for applications that are used internally. Any software development costs that are incurred prior to the point where the project has demonstrated technological feasibility are expensed as they are incurred. Once technological feasibility has been established, development costs are capitalized. Once development is complete and the software is made available for release to customers, capitalization is no longer appropriate because any remaining costs are considered ongoing maintenance and support. These are expensed as they are incurred. The definition of “technological feasibility”, per ASC 985 or ASC 350, is “the technological feasibility of a computer software product is established when the entity has completed all planning, designing, coding, and testing activities that are necessary to establish that the product can be produced to meet its design specifications including functions, features, and technical performance requirements.” Software development costs are subject to these rules regardless of whether the costs were generated internally (employee time) or externally (vendor fees).
Foreign Currency Translation	Foreign Currency TranslationThe functional currency for all our subsidiaries is the U.S. dollar. Gains and losses resulting from the remeasurement of foreign currency amounts to the functional currency are included in operating expenses in the consolidated statements of comprehensive loss. Gains and losses resulting from translating assets and liabilities from the functional currency to U.S. dollars are included in Foreign currency translation adjustment in the consolidated statements of operations and comprehensive loss.
Government Grants	Government Grants The Company accounts for government grants and loans as debt until it is reasonably assured that all or a portion of the loan will be forgiven, often indicated by a notice received from the government agency in question that the amount has been forgiven. At that time, the amount that is forgiven is converted from debt and recognized as grant income. The Company does not impute interest on government loans if the rate is determined to be below-market due to the scope exemption for government-mandated interest rates.
Convertible Debt	Convertible Debt The Company accounts for convertible debt and related transactions in accordance with ASC 470-20, Debt with Conversion and Other Options, ASC 815, Derivatives and Hedging, and ASC 480, Distinguishing Liabilities from Equity. The Company evaluates convertible debt instruments and related transactions at inception to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. Convertible debt instruments that may be settled in cash are separated into liability and equity components. The allocation to the liability component is based on the fair value of a similar instrument that does not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs are then allocated to the liability and equity components in a similar manner. The difference between the principal amount of the convertible debt instruments and the liability component, inclusive of issuance costs, represents the debt discount, which is amortized to interest expense over the term of instruments. The determination of the discount rate requires certain estimates and assumptions.
Pharmacy Technology Revenue Recognition and Retail Pharmacy Revenue Recognition	Pharmacy Technology Revenue Recognition The Company accounts for revenue under Accounting Standards Codification, or ASC, Topic 606: Revenue from Contracts with Customers, or Topic 606. The amount of revenue recognized for any goods or services reflects the consideration that the Company expects to be entitled to receive in exchange for those goods and services. To achieve this core principle, the Company applies the following five-step approach: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as a performance obligation is satisfied. A contract is accounted for when approved by both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Performance obligations under a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. In certain instances, the Company concluded that distinct goods or services should be accounted for as a single performance obligation that is a series of distinct goods or services that have the same pattern of transfer to the customer. The transaction price is determined based on the consideration that the Company will be entitled to in exchange for transferring goods or services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price, utilizing the expected value method. During 2021 and 2020, none of our pharmacy technology contracts included variable consideration. Determining the transaction price requires judgment. The Company must also determine if the promises to transfer the goods or services to the customer are separately identifiable from other promises in the contract (the goods or services are distinct in the context of the contract). If these criteria are not met, the promised services are accounted for as a single performance obligation. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price (SSP) basis. We determine each SSP based on the Company’s history of selling such performance obligations as standalone goods or services. When no observable evidence exists, we estimate SSP using cost-plus method. In cases where the cost-plus method is used, to establish the gross margins we utilize all observable data points including, market and industry data points and the Company’s pricing practices. Subscription Revenue The Company provides MedCenter units to customers on a contract that includes software license and maintenance services or a Subscription Agreement. Subscription Agreements include operating leases for the MedCenter units with a non-cancelable term of 12 months or less, and are recorded following lessor guidance for operating leases. MedCenters leased to customers are carried on the Company’s consolidated balance sheets as MedCenter equipment and depreciated. For the years ended December 31, 2021 and 2020, subscription revenue was $0.4 million and $0.5 million, respectively, within the pharmacy and hardware revenue on the consolidated statements of operations and comprehensive loss. MedCenter Revenue The Company derives revenue from the sale of MedPlatform Systems, which include MedCenter prescription dispensing kiosks, and the associated installation, software, maintenance and support, and professional service components necessary for operation, representing multiple distinct performance obligations. Hardware and installation revenue is recognized when the MedCenter is delivered, installed, and controlled by the customer. Software, and maintenance and support revenue is recognized over the term of the MedCenter Systems contract. Professional service revenue is recognized on a proportional performance, time-and-materials basis, as the services are delivered to the customer. For any consideration received prior to the fulfillment of the obligation, deferred revenue is recorded. As of December 31, 2021 and 2020, the consolidated balance sheets included $0.1 million and $0.3 million, respectively, of deferred revenue. Retail Pharmacy Revenue Recognition The Company recognizes revenue, net of sales taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. Revenue from the sale of the pharmaceutical products is recorded at a transaction price which includes an estimate of direct and indirect remuneration fees or DIR fees associated with prescription drugs dispensed during the year. DIR fees are calculated by pharmacy benefit managers or PBMs after the sale is completed pursuant to contract terms. The DIR fees under these arrangements are estimated at the time of sale and recognized as a reduction in revenue. Management developed the estimated provisions for revenue reserves based on historical trends adjusted for product mix and PBM mix.
Inventory	Inventory Inventory used in the retail pharmacy services segment consists of pharmaceuticals, which are carried at the lower of cost (first in, first out) or net realizable value.
Impairment of Long Lived Assets	Impairment of Long Lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable, the Company compares the carrying amount of an asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are carried at cost less accumulated depreciation and impairment. Gains and losses arising on the disposal of individual assets are recognized in income in the period of disposal. Costs, including financing charges and certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction-in-progress and are not subject to depreciation. Depreciation begins when an asset is placed into service on a straight-line basis over the estimated useful lives as follows: IT equipment 1 – 3 years General plant and equipment 5 – 8 years Vehicles 5 years Office furniture and equipment 5 – 8 years Leasehold improvements lesser of useful life or term of lease MedCenter equipment 8 years Maintenance and repairs are charged to expense as incurred. Renewals and betterments that materially prolong the useful lives of the assets are capitalized. The cost and related accumulated depreciation of property retired or sold are removed from the accounts, and gains or losses are recognized in the consolidated statements of operations.
Intangible Assets	Intangible AssetsIntangible assets consist of software, patents and know-how. Intangible assets acquired through asset acquisitions or business combinations are initially recognized at fair value based on an allocation of the purchase price. Software includes internal and external use software costs that are accounted for in accordance with ASC 350 and ASC 925, respectively. Costs associated with application development are capitalized as intangible assets. All other costs including planning, training, and conceptual evaluation are expensed. The intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization of the intellectual property commenced in 2014 on delivery of the first proof of concept MedCenter. The Company evaluates the reasonableness of the estimated useful lives of these intangible assets on an annual basis.
Leases	Leases The Company maintains operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, and certain equipment. ASC 842 requires lessees to recognize a right-of-use, or ROU, asset and a lease liability on the balance sheet for substantially all leases, except for short-term leases. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. New contracts are analyzed to determine whether they include leased assets; such leases are referred to as embedded leases. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicitly or implicitly identified asset in the contract and if the Company controls the use of that asset. The Company’s accounting policy treats leases with an initial term of 12 months or less as short-term leases. Lease expense for short-term lease payments are recognized on a straight-line basis over the term of the lease. Operating lease right-of-use, or ROU, assets and lease liabilities are recognized based on the present value of lease payments over the lease term. Because most of the leases do not include an implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments. As a practical expedient, the Company has elected not to separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs). As a result, if the non-lease components are fixed, they are included when calculating the ROU asset and related lease liability. See Note 12 for additional disclosures.
Share-based compensation	Share-based compensation The Company has a stock compensation plan whereby awards are granted to certain employees. The fair value of the stock options and restricted stock units or RSUs granted by the Company to employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. The fair value of the options and RSU’s are measured using the Black-Scholes option pricing model and intrinsic value, respectively, as of the grant date date. Shares issued upon the exercise of options and vesting of RSUs are new shares. Forfeitures are estimated based on historical experience and expense related to awards, and the estimate is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are fully expensed.
Warrants	Warrants The Company issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards once issued. Certain obligations to issue warrants as compensation for services may be initially classified as liabilities before the warrants are issued. The fair value of the awards are measured using the Black-Scholes option pricing model as of the grant date. Warrants issued on November 12, 2020 to a service provider were valued based on the liability settled with their issuance. Warrants issued are initially recorded at fair value as a reduction to additional paid in capital or as an expense if the warrants are issued to pay for services.
Financing costs	Financing costsFinancing costs incurred to issue debt are capitalized and amortized using the effective interest method until the individual financial liability matures and are included as a component of interest expense in the consolidated statements of operations and comprehensive loss. Financing costs incurred to issue equity are capitalized and netted against the respective class of shares they were incurred to issue.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). This guidance removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU was effective beginning in the first quarter of our fiscal year 2021. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings(deficit) in the period of adoption. The Company assessed the impact of the new accounting standard on its consolidated financial statements to facilitate its required adoption of the new standard on January 1, 2021. The adoption of ASU 2019-12 did not result in a material change to our consolidated financial statements. Debt with Conversion and Other Options In August 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting For Convertible Instruments and Contracts in an Entity's Own Equity” (“ASU 2020-06”). The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per share calculation in certain areas. The Company assessed the impact of the new accounting standard on its consolidated financial statements to facilitate its early adoption of the new standard on January 1, 2021. As the Company has no outstanding convertible debt at the date of adoption, ASU 2020-06 did not impact our consolidated financial statements. Recently Issued Accounting Standards Not Yet Adopted Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, excluding smaller reporting companies. For all other entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The effect of the reclassifications within the consolidated statement of operations and comprehensive loss for 2020 is as follows (in thousands): Year Ended December 31, 2020 Current presentation As previously reported Change Pharmacy operations $ 6,146 $ 5,687 $ 459 General and administrative 15,863 16,562 (699) Selling and marketing 3,283 3,043 240 $ 25,292 $ 25,292 $ —

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Property, Plant and Equipment and Useful Lives	Depreciation begins when an asset is placed into service on a straight-line basis over the estimated useful lives as follows: IT equipment 1 – 3 years General plant and equipment 5 – 8 years Vehicles 5 years Office furniture and equipment 5 – 8 years Leasehold improvements lesser of useful life or term of lease MedCenter equipment 8 years The following tables present property, plant and equipment balances (in thousands): Estimated useful lives December 31, December 31, 2021 2020 Property, plant and equipment: MedCenter equipment 8 years $ 5,875 $ 4,622 IT equipment 1 - 3 years 2,361 1,999 Leasehold improvements lesser of useful life or term of lease 880 799 General plant and equipment 5 - 8 years 603 353 Office furniture and equipment 5 - 8 years 394 329 Vehicles 5 years 54 54 Construction-in-process 1,021 90 Total historical cost 11,188 8,246 Accumulated depreciation (5,496) (4,451) Total property, plant and equipment, net $ 5,692 $ 3,795
Schedule of Finite-Lived Intangible Assets	Amortization is recorded from the date each asset is placed into service on a straight-line basis over the estimated useful lives of intangible assets as follows: Intellectual property 6 years Website and mobile application 2 years Software 1 – 5 years

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Warrants Included in Earnings per Share	The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding
Schedule of Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share (in thousands, expect for share and per share amounts): Year Ended December 31, 2021 2020 Net loss - basic and diluted $ (43,815) $ (26,810) Weighted average shares - basic and diluted 32,656,325 5,722,095 Net loss per share - basic and diluted $ (1.34) $ (4.69)

FAIR VALUE MEASUREMENTS AND F_2

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	Assets and liabilities measured at fair value on a recurring basis were as follows (in thousands): Fair Value Hierarchy December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ — Fair Value Hierarchy December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 57,936 $ 57,936 $ — $ — Restricted cash 60 60 — — Total assets $ 57,996 $ 57,996 $ — $ —

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	The following table presents details of accounts payable and accrued liabilities (in thousands): December 31, 2021 2020 Accounts payable and accrued liabilities: Payroll $ 2,733 $ 2,760 Trade accounts payable 4,007 1,752 Total accounts payable and accrued liabilities $ 6,740 $ 4,512

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	The following table presents detail of inventory balances (in thousands): December 31, 2021 2020 Inventory: MedCenter hardware $ 1,201 $ 1,655 Pharmaceuticals 2,150 837 Spare parts 565 325 Total inventory $ 3,916 $ 2,817

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment and Useful Lives	Depreciation begins when an asset is placed into service on a straight-line basis over the estimated useful lives as follows: IT equipment 1 – 3 years General plant and equipment 5 – 8 years Vehicles 5 years Office furniture and equipment 5 – 8 years Leasehold improvements lesser of useful life or term of lease MedCenter equipment 8 years The following tables present property, plant and equipment balances (in thousands): Estimated useful lives December 31, December 31, 2021 2020 Property, plant and equipment: MedCenter equipment 8 years $ 5,875 $ 4,622 IT equipment 1 - 3 years 2,361 1,999 Leasehold improvements lesser of useful life or term of lease 880 799 General plant and equipment 5 - 8 years 603 353 Office furniture and equipment 5 - 8 years 394 329 Vehicles 5 years 54 54 Construction-in-process 1,021 90 Total historical cost 11,188 8,246 Accumulated depreciation (5,496) (4,451) Total property, plant and equipment, net $ 5,692 $ 3,795

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets by Major Class	The following table presents intangible asset balances (in thousands): December 31, 2021 2020 Gross intangible assets: Software $ 4,475 $ 1,815 Intellectual property 3,857 3,857 Website and mobile application 583 583 Total intangible assets 8,915 6,255 Accumulated amortization: Software (2,175) (1,588) Intellectual property (3,857) (3,857) Website and mobile application (583) (583) Total accumulated amortization (6,615) (6,028) Total net book value $ 2,300 $ 227
Schedule of Amortization Expense for the Intangible Assets	Amortization expense for the intangible assets is expected to be as follows over the next five years, and thereafter (in thousands): December 31, 2021 2022 $ 413 2023 289 2024 282 2025 278 2026 122 Thereafter — Work-in-process 916 Total estimated amortization expense $ 2,300

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of lease assets and liabilities	Balance sheet amounts for lease assets and leases liabilities are as follows (in thousands): December 31, 2021 2020 Assets Operating: $ 2,376 $ 1,108 Finance: 162 131 Total assets $ 2,538 $ 1,239 Liabilities: Operating: Current 599 612 Long-term 1,947 572 Finance: Current 83 53 Long-term 80 79 Total liabilities $ 2,709 $ 1,316 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: December 31, 2021 2020 Finance leases: Weighted-average remaining lease term (years) 1.5 2.4 Weighted-average discount rate 8.8 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 4.2 2.5 Weighted-average discount rate 6.9 % 6.0 %
Schedule of maturities of operating lease liabilities	Maturities of operating lease liabilities are as follows (in thousands): December 31, 2021 2022 $ 773 2023 714 2024 562 2025 478 2026 410 Thereafter 24 Total lease payments 2,961 Less: present value discount (415) Total leases $ 2,546
Schedule of maturities of finance lease liabilities	Maturities of finance lease liabilities are as follows (in thousands): December 31, 2021 2022 $ 93 2023 65 2024 22 2025 — 2026 — Thereafter — Total finance lease payments 180 Less: imputed interest (17) Total leases $ 163

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Debt	The following table presents debt balances (in thousands): December 31, 2021 2020 Term loan $ 10,070 $ — Term loan discount (532) — Convertible promissory note due March 2021 — — Short-term note due May 2021 — 1,000 Short-term note due November 2021 — 1,000 PPP loan — 161 Total debt 9,538 2,161 Less Short-term debt — 2,161 Long-term debt $ 9,538 $ —

PHARMACY OPERATIONS EXPENSES (T

PHARMACY OPERATIONS EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Schedule Of Pharmacy Operations Expense	Pharmacy operations expenses are as follows (in thousands): Year Ended December 31, 2021 2020 Pharmacy operations expenses: Wages and salaries $ 9,844 $ 4,486 Other pharmacy operations expenses 1,374 612 Depreciation of property, plant and equipment 826 655 Rent and utilities 558 275 Repairs and maintenance 316 97 Amortization of intangible assets 578 21 Total pharmacy operations expenses $ 13,496 $ 6,146

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Schedule Of Selling, General, and Administrative Expense By Component	General and administrative expenses are as follows (in thousands): Year Ended December 31, 2021 2020 General and administrative expenses: Wages and salaries $ 10,980 $ 9,682 Professional services 3,457 2,001 Insurance 1,780 503 Rent and utilities 1,338 1,242 Other general and administrative expenses 1,021 669 Share-based compensation 1,205 380 Software licenses and support 1,179 419 Travel and other employee expenses 736 359 Office and IT supplies 393 441 Depreciation of property, plant and equipment 188 167 Total general and administrative expenses $ 22,277 $ 15,863

OTHER GAIN (LOSS) (Tables)

OTHER GAIN (LOSS) (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Schedule of Other Gain (Loss)	Other gain (loss) is as follows (in thousands): Year Ended December 31, 2021 2020 Other gain (loss), net Forgiveness of PPP Loan $ 161 $ 181 Other gain (loss), net 45 (291) Total other gain (loss), net $ 206 $ (110)

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income Tax Reconciliation	The provision for income taxes in the consolidated statement of operations and comprehensive loss represents an effective rate different from the US statutory tax rate for the following reasons (in thousands): Year Ended December 31, 2021 2020 Loss before income taxes $ (43,813) $ (26,810) Income tax recovery at statutory rate (21%) (9,201) (5,630) State income tax expense, net of federal benefit (1,955) — Increase resulting from: Effect of foreign tax rate (610) (252) Unrecognized deferred tax asset 14,356 5,642 Permanent and other differences (2,588) 240 Provision for income taxes $ 2 $ —
Schedule of Future Income Tax Assets and Liabilities	The effects of temporary differences that give rise to future income tax assets and future income tax liabilities have been determined as follows (in thousands): Year Ended December 31, 2021 2020 Future income tax assets: Non-capital losses $ 44,590 $ 31,658 Un-depreciated capital cost (UCC) 1,525 1,868 Other intangible items 1,556 223 Interest limitation carryforward 463 — Total future income tax assets 48,134 33,749 Future income tax liabilities: Unrecognized deferred tax asset (48,134) (33,749) Net future income tax asset $ — $ —
Unrecognized Deferred Tax Assets Rollforward	A reconciliation of the beginning and ending amounts of unrecognized deferred tax benefits is as follows (in thousands): Year Ended December 31, 2021 2020 Beginning balance $ 33,749 $ 27,672 Additions based on tax positions related to the current year 14,385 6,077 Ending balance $ 48,134 $ 33,749 The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefit as a component of income tax expense. The Company does not expect any significant changes to the unrecognized tax benefits within the next 12 months.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedules of Concentration of Risk, by Risk Factor	The following table presents the Company’s vendor concentration: Year Ended December 31, 2021 2020 Vendor A 32 % 26 % Vendor B — % 15 % Vendor C 12 % — %

REDEEMABLE PREFERRED STOCK, D_2

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Preferred Shares	The following table presents changes in preferred shares outstanding (in thousands, except share amounts): Preferred Shares Shares Amount Balance at December 31, 2019 10,500,440 $ 93,484 Issued 102,777 788 Converted to common shares in Merger (10,603,217) (94,272) Balance at December 31, 2020 — $ —
Schedule of Stock Conversion	On November 17, 2020, all shares of preferred stock were converted to common shares as follows: Shares Before Conversion Conversion Ratio Common Shares Issued Series A preferred stock 1,175,544 1.00 1,175,544 Series B preferred stock 2,222,886 1.00 2,222,886 Series C preferred stock 1,634,249 1.54 2,517,665 Series D preferred stock 502,630 1.62 813,050 Series E preferred stock 5,067,908 1.00 5,067,910 Total 10,603,217 11,797,055
Schedule Of Dividend Rights By Class Of Stock	The annual dividend rate by series is as follows: Series A $ 0.41 CAD Series B $ 0.57 CAD Series C $ 1.36 CAD Series D $ 1.42 CAD Series E $ 0.88 CAD
Schedule Of Temporary Equity Liquidation Rights	The amount received per share is as follows: Series A $ 5.13 CAD Series B $ 7.10 CAD Series C $ 16.95 CAD Series D $ 17.79 CAD Series E $ 11.00 CAD
Schedule Of Temporary Equity Conversion Rates	Conversion rates are as follows: Series A $ 5.13 CAD Series B $ 7.10 CAD Series C $ 11.00 CAD Series D $ 11.00 CAD Series E $ 11.00 CAD
Schedule of Assumptions in Valuation of Stock Options Granted	The key input assumptions that were utilized in the valuation of the stock options granted in the periods presented are as follows: December 31, 2021 Low Weighted Average High Total Awards Granted 1,003,130 Weighted Average Fair Value of Awards $ 3.32 Unvested Forfeiture Rate 6.00 % 6.00 % 6.00 % Grant Price $ 1.70 $ 6.07 $ 15.15 Market Price $ 1.70 $ 6.07 $ 15.15 Volatility 60 % 60 % 60 % Risk Free Rate 0.46 % 1.12 % 1.36 % Dividend Yield — % — % — % Expected Life 5.17 5.94 6 December 31, 2020 Low Weighted Average High Total Awards Granted 442,830 Weighted Average Fair Value of Awards $ 0.72 Unvested Forfeiture Rate 6.00 % 6.00 % 6.00 % Grant Price $ 1.34 $ 1.34 $ 1.34 Market Price $ 1.34 $ 1.34 $ 1.34 Volatility 60 % 60 % 60 % Risk Free Rate 0.43 % 0.43 % 0.44 % Dividend Yield — % — % — % Expected Life 5.87 5.92 6.02
Schedule of Assumptions in Valuation of Awards Other than Options Granted	The key input assumptions that were utilized in the valuation of the RSUs granted in the periods presented are as follows: December 31, 2021 Low Weighted Average High Total Awards Granted 852,395 Weighted Average Fair Value of Awards $ 3.35 Unvested Forfeiture Rate 6.00 % 6.00 % 6.00 % Grant Price $ — $ — $ — Market Price $ 1.70 $ 3.35 $ 15.15
Schedule of Outstanding Awards Activity	The following table present outstanding stock option awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding, beginning of period 2,439,020 $ 1.56 $ 0.76 $ 32,894 Granted 1,003,130 $ 6.07 $ 3.32 $ — Exercised (237,330) $ 1.67 $ 9.90 $ 0.81 $ 1,954 Cancelled/Forfeited (335,971) $ 4.75 $ 2.58 $ 392 Expired (19,946) $ 1.65 $ 0.77 $ 20 Outstanding, end of period 2,848,903 $ 2.78 $ 1.44 7.61 $ 31 Vested and exercisable, end of the period 1,834,645 $ 1.95 $ 0.95 6.64 $ 24 Vested and unvested exercisable, end of the period 1,834,645 $ 1.95 $ 0.95 6.64 $ 24 Vested and expected to vest, end of the period 2,754,222 $ 2.74 $ 1.42 7.55 $ 31 The following table present the outstanding stock option awards activity during the year ended December 31, 2020: Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding, beginning of period 2,391,401 $ 1.59 $ 0.76 $ — Granted 442,830 $ 1.34 $ 0.72 $ 4,960 Exercised (160,090) $ 1.84 $ 11.09 $ 0.98 $ 1,482 Cancelled/Forfeited (235,121) $ 1.63 $ 0.76 $ 2,886 Outstanding, end of period 2,439,020 $ 1.56 $ 0.76 8.2 $ 32,894 Vested and exercisable, end of the period 1,745,376 $ 1.63 $ 0.78 7.9 $ 23,428 Vested and unvested exercisable, end of the period 1,745,376 $ 1.63 $ 0.78 7.9 $ 23,428 Vested and expected to vest, end of the period 2,386,417 $ 1.57 $ 0.76 8.2 $ 32,175 The following table present outstanding RSU awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding, beginning of period — $ — $ — Granted 852,395 $ 3.35 $ 2,858 Exercised (11,155) $ 1.93 $ 11.58 $ 22 Cancelled/Forfeited (38,500) $ 12.83 $ 138 Outstanding, end of period 802,740 $ 2.78 $ 1,124 Vested and exercisable, end of the period — $ — $ — Vested and unvested exercisable, end of the period — $ — $ — Vested and expected to vest, end of the period 717,476 $ 2.81 4.9 $ 1,005
Schedule of Nonvested Share Activity	The following table present unvested stock option awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Amortization Period (Years) Unvested outstanding, beginning of period 693,644 $ 1.40 $ 0.69 Granted 1,003,130 $ 6.07 $ 3.32 Cancelled/Forfeited (333,565) $ 4.77 $ 2.59 Expired (19,946) $ 1.65 $ 0.77 Vested, outstanding shares (329,005) $ 3.36 $ 1.71 Unvested outstanding, end of period 1,014,258 $ 4.28 $ 2.34 3.11 The following table presents unvested stock option awards activity during the year ended December 31, 2020: Number of Awards Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Amortization Period (Years) Unvested Outstanding, beginning of period 712,559 $ 1.44 $ 0.68 Granted 442,830 $ 1.34 $ 0.72 Cancelled/Forfeited (18,481) $ 1.54 $ 0.76 Vested, outstanding shares (443,264) $ 1.44 $ 0.72 Unvested Outstanding, end of period 693,644 $ 1.40 $ 0.69 2.5 The following table present unvested RSU awards activity during the year ended December 31, 2021: Number of Awards Weighted Average Grant Date Fair Value Weighted Average Remaining Amortization Period (Years) Unvested outstanding, beginning of period — $ — Granted 852,395 $ 3.35 Cancelled/Forfeited (38,500) $ 12.83 Vested, outstanding shares (11,155) $ 11.58 Unvested outstanding, end of period 802,740 $ 2.78 2.7
Schedule of MedAvail Share-based Compensation Expense	The following table presents expense related to share-based compensation: Year Ended December 31, 2021 2020 Share-based compensation $ 1,205 $ 380
Schedule of Warrants Issued	During the year ended December 31, 2020 warrants issued were as follows: Year Ended December 31, 2020 Issue Date Reason for issuance Amount Term (years) Exercise Price 2/11/2020 Equity offering 27,427 10.0 $ 1.57 2/11/2020 Payment for services 309,698 10.0 $ 0.01 2/19/2020 Payment for services 6,855 10.0 $ 1.57 5/26/2020 Issuance of promissory note 115,374 0.5 $ 1.57 6/4/2020 Payment for services 16,119 10.0 $ 1.57 6/9/2020 Issuance of promissory note 1,676 0.5 $ 1.57 6/10/2020 Issuance of promissory note 761 0.5 $ 1.57 6/17/2020 Issuance of promissory note 319 0.5 $ 1.57 6/29/2020 Payment for services 84,911 10.0 $ 0.01 7/2/2020 Bridge financing 2,285 10.0 $ 1.57 8/14/2020 Bridge financing 1,524 10.0 $ 1.57 8/21/2020 Bridge financing 2,285 10.0 $ 1.57 10/2/2020 Bridge financing 6,857 10.0 $ 1.57 10/6/2020 Bridge financing 61,331 10.0 $ 1.57 10/7/2020 Bridge financing 381 10.0 $ 1.57 11/12/2020 Option cancellation 201,648 8.0 $ 1.57 11/18/2020 Payment for services 58,518 5.0 $ 0.01 December 31, 2021 December 31, 2020 Warrants Exercise price Term (years) Warrants Exercise price Term (years) Common 19,310 $ 0.01 571,355 $ 0.01 Common — $ 6.93 288,352 $ 6.93 Common 224,852 $ 1.66 260,250 $ 1.66 Common 493,173 $ 1.57 557,598 $ 1.57 Total 737,335 $ 1.56 7.6 1,677,555 $ 1.97 7.8

REVENUE AND SEGMENT REPORTING (

REVENUE AND SEGMENT REPORTING (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Schedule of Revenue and Costs of Sales by Segment	The following table presents revenue and costs of revenue by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Year Ended December 31, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 20,203 $ — $ 20,203 Hardware — 470 470 Subscription — 446 446 Total pharmacy and hardware revenue 20,203 916 21,119 Service revenue: Software integration — — — Software — 259 259 Maintenance and support — 161 161 Installation — 39 39 Professional services and other — 551 551 Total service revenue — 1,010 1,010 Total revenue 20,203 1,926 22,129 Cost of products sold and services 20,031 1,781 21,812 Segment gross profit $ 172 $ 145 317 Operating expense: Pharmacy operations 13,496 General and administrative 22,277 Selling and marketing 7,204 Research and development 849 Merger expenses — Total operating expense 43,826 Operating loss $ (43,509) Retail Pharmacy Services Pharmacy Technology Total Year Ended December 31, 2020 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 7,728 $ — $ 7,728 Hardware — 2,401 2,401 Subscription — 467 467 Total pharmacy and hardware revenue 7,728 2,868 10,596 Service revenue: Software integration — 3,168 3,168 Software — 44 44 Maintenance and support — 58 58 Installation — 55 55 Professional services and other — 47 47 Total service revenue — 3,372 3,372 Total revenue 7,728 6,240 13,968 Cost of products sold and services 7,744 1,061 8,805 Segment gross profit $ (16) $ 5,179 5,163 Operating expense: Pharmacy operations 6,146 General and administrative 15,863 Selling and marketing 3,283 Research and development 682 Merger expenses 4,691 Total operating expense 30,665 Operating loss $ (25,502)
Schedule of Assets and Liabilities by Segment	The following table presents assets and liabilities by segment (In thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 December 31, 2020 Assets $ 6,012 $ 5,547 $ 57,772 $ 69,331 Liabilities $ 2,203 $ 3,422 $ 2,639 $ 8,264 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): Year Ended December 31, 2021 2020 Long-lived assets: United States $ 7,675 $ 4,533 Canada $ 555 $ 501 Total long-lived assets $ 8,230 $ 5,034

NATURE OF OPERATIONS (Details)

NATURE OF OPERATIONS (Details) - USD ($) $ in Thousands	Nov. 17, 2020	Jun. 29, 2020	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Issuance of common shares in private placement		$ 83,900	$ 0	$ 83,900
Repayment of debt			$ 2,000	$ 14,134
MYOS RENS
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash payment for Merger	$ 2,000
Promissory note issued for Merger	3,000
MYOS Promissory Note | Loans Payable
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Repayment of debt	$ 1,000
MYOS RENS | Former MedAvail Security Holders
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Merger agreement, percentage of ownership after transaction	96.80%
MYOS RENS | Former Shareholders of MYOS
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Merger agreement, percentage of ownership before transaction	3.20%

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jun. 07, 2021
Debt Instrument [Line Items]
Cash and cash equivalents	$ 19,689,000	$ 57,936,000
Accumulated deficit	192,090,000	148,275,000
Net cash used in operating activities	(42,519,000)	$ (28,634,000)
Term loan | Secured Debt
Debt Instrument [Line Items]
Principal amount	10,000,000		$ 10,000,000
Additional borrowing capacity available	$ 20,000,000		$ 20,000,000

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	Nov. 17, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock split, conversion ratio	1.26

BASIS OF PRESENTATION- Reclassi

BASIS OF PRESENTATION- Reclassifications (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations	$ 13,496	$ 6,146
General and administrative	22,277	15,863
Selling and marketing	$ 7,204	3,283
Total		25,292
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		5,687
General and administrative		16,562
Selling and marketing		3,043
Total		25,292
Change
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		459
General and administrative		(699)
Selling and marketing		240
Total		$ 0

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Restricted cash	$ 400,000	$ 60,000
Allowance for doubtful accounts	66,000	40,000
Total revenue	22,129,000	13,968,000
Deferred revenue	83,000	275,000
Pharmacy Technology
Related Party Transaction [Line Items]
Total revenue	1,926,000	6,240,000
Subscription
Related Party Transaction [Line Items]
Total revenue	446,000	467,000
Subscription | Pharmacy Technology
Related Party Transaction [Line Items]
Total revenue	446,000	467,000
Employees
Related Party Transaction [Line Items]
Related party accounts receivable	0	$ 300,000
Guarantee for Purchasing Cards
Related Party Transaction [Line Items]
Cash released from restriction	60,000
Letter of Credit Security
Related Party Transaction [Line Items]
Restricted cash	$ 400,000

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES - Property Plant and Equipment, Useful Life (Details)	12 Months Ended
	Dec. 31, 2021
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	3 years
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Useful Life (Details)	12 Months Ended
	Dec. 31, 2021
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets	6 years
Website and mobile application
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets	2 years
Minimum | Software
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets	1 year
Maximum | Software
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets	5 years

EARNINGS (LOSS) PER SHARE - War

EARNINGS (LOSS) PER SHARE - Warrants Included in Earnings per Share (Details)	12 Months Ended
	Dec. 31, 2021shares
Warrants Issued May 9, 2018
Class of Warrant or Right [Line Items]
Warrants (in shares)	118,228
Warrants Issued February 11, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	309,698
Warrants Issued June 29, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	84,911
Warrants Issued November 18, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	39,208
Warrants Issued November 18, 2020, Outstanding
Class of Warrant or Right [Line Items]
Warrants (in shares)	19,310

EARNINGS (LOSS) PER SHARE - Nar

EARNINGS (LOSS) PER SHARE - Narrative (Details) shares in Millions	Nov. 17, 2020	Dec. 31, 2021shares	Dec. 31, 2020shares
Class of Warrant or Right [Line Items]
Stock split, conversion ratio	1.26
Weighted Average
Class of Warrant or Right [Line Items]
Potentially dilutive option awards excluded from earnings per share calculation (in shares)		2.8	2.6

EARNINGS (LOSS) PER SHARE - Cal

EARNINGS (LOSS) PER SHARE - Calculation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net loss - basic and diluted	$ (43,815)	$ (26,810)
Net loss - basic and diluted	$ (43,815)	$ (26,810)
Weighted average shares outstanding - basic (in shares)	32,656,325	5,722,095
Weighted average shares outstanding - diluted (in shares)	32,656,325	5,722,095
Net loss per share - basic (in USD per share)	$ (1.34)	$ (4.69)
Net loss per share - diluted (in USD per share)	$ (1.34)	$ (4.69)

FAIR VALUE MEASUREMENTS AND F_3

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 19,689	$ 57,936
Restricted cash	400	60
Total assets	20,089	57,996
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	19,689	57,936
Restricted cash	400	60
Total assets	20,089	57,996
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	$ 0	$ 0

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Payroll	$ 2,733	$ 2,760
Trade accounts payable	4,007	1,752
Total accounts payable and accrued liabilities	$ 6,740	$ 4,512

INVENTORY - Schedule of Invento

INVENTORY - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
MedCenter hardware	$ 1,201	$ 1,655
Pharmaceuticals	2,150	837
Spare parts	565	325
Total inventory	$ 3,916	$ 2,817

INVENTORY - Narrative (Details)

INVENTORY - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Inventory [Line Items]
Provisions for inventory	$ 626	$ 219
Pharmacy
Inventory [Line Items]
Inventory recognized as cost of sales	18,500	7,300
Hardware
Inventory [Line Items]
Inventory recognized as cost of sales	$ 1,100	$ 700

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total historical cost	$ 11,188	$ 8,246
Accumulated depreciation	(5,496)	(4,451)
Total property, plant and equipment, net	$ 5,692	3,795
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Total historical cost	$ 5,875	4,622
IT equipment
Property, Plant and Equipment [Line Items]
Total historical cost	$ 2,361	1,999
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total historical cost	$ 880	799
General plant and equipment
Property, Plant and Equipment [Line Items]
Total historical cost	$ 603	353
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Total historical cost	$ 394	329
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Total historical cost	$ 54	54
Construction-in-process
Property, Plant and Equipment [Line Items]
Total historical cost	$ 1,021	$ 90

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Inventory transferred to property, plant and equipment	$ 1,817	$ 1,520
Property, plant and equipment, net	5,692	3,795
Accumulated depreciation	5,496	4,451
Depreciation of property, plant, and equipment	1,174	1,016
Depreciation included in cost of sales	200	200
Leased MedCenter Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	1,700	700
Accumulated depreciation	$ 1,000	$ 300

INTANGIBLE ASSETS - Intangible

INTANGIBLE ASSETS - Intangible Asset Balances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Acquired Indefinite-lived Intangible Assets [Line Items]
Total intangible assets	$ 8,915	$ 6,255
Accumulated amortization	(6,615)	(6,028)
Total net book value	2,300	227
Amortization of intangible assets	600	100
Software
Acquired Indefinite-lived Intangible Assets [Line Items]
Total intangible assets	4,475	1,815
Accumulated amortization	(2,175)	(1,588)
Intellectual property
Acquired Indefinite-lived Intangible Assets [Line Items]
Total intangible assets	3,857	3,857
Accumulated amortization	(3,857)	(3,857)
Website and mobile application
Acquired Indefinite-lived Intangible Assets [Line Items]
Total intangible assets	583	583
Accumulated amortization	$ (583)	$ (583)

INTANGIBLE ASSETS - Future Amor

INTANGIBLE ASSETS - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 413
2023	289
2024	282
2025	278
2026	122
Thereafter	0
Work-in-process	916
Total net book value	$ 2,300	$ 227

LEASES - Narrative (Details)

LEASES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Feb. 28, 2022
Lessee, Lease, Description [Line Items]
Operating lease, expense	$ 900	$ 800
Operating lease right-of-use asset	2,376	$ 1,108
Operating lease liability	$ 2,546
Subsequent Event
Lessee, Lease, Description [Line Items]
Operating leases term			64 months
Operating lease right-of-use asset			$ 200
Operating lease liability			$ 200
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, average remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, average remaining lease term	5 years

LEASES - Balance Sheet Informat

LEASES - Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Assets	Assets
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Assets	Assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of lease obligations	Current portion of lease obligations
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term portion of lease obligations	Long-term portion of lease obligations
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of lease obligations	Current portion of lease obligations
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term portion of lease obligations	Long-term portion of lease obligations
Assets
Operating:	$ 2,376	$ 1,108
Finance:	162	131
Assets	2,538	1,239
Operating:
Current	599	612
Long-term	1,947	572
Finance:
Current	83	53
Long-term	80	79
Total liabilities	$ 2,709	$ 1,316

LEASES - Additional Lease Infor

LEASES - Additional Lease Information (Details)	Dec. 31, 2021	Dec. 31, 2020
Finance leases:
Weighted-average remaining lease term (years)	1 year 6 months	2 years 4 months 24 days
Weighted-average discount rate	8.80%	6.00%
Operating leases:
Weighted-average remaining lease term (years)	4 years 2 months 12 days	2 years 6 months
Weighted-average discount rate	6.90%	6.00%

LEASES - Operating Lease Liabil

LEASES - Operating Lease Liability, Maturities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Leases [Abstract]
2022	$ 773
2023	714
2024	562
2025	478
2026	410
Thereafter	24
Total lease payments	2,961
Less: present value discount	(415)
Total leases	$ 2,546

LEASES - Finance Lease Liabilit

LEASES - Finance Lease Liability, Maturities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Leases [Abstract]
2022	$ 93
2023	65
2024	22
2025	0
2026	0
Thereafter	0
Total finance lease payments	180
Less: imputed interest	(17)
Total leases	$ 163

DEBT - Schedule of Debt (Detail

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt	$ 9,538	$ 2,161
Less Short-term debt	0	2,161
Long-term debt	9,538	0
Term loan | Secured Debt
Debt Instrument [Line Items]
Debt instrument, gross	10,070	0
Term loan discount	(532)	0
Convertible promissory note due March 2021 | Convertible Subordinated Debt
Debt Instrument [Line Items]
Debt instrument, gross	0	0
Short-term note due May 2021 | Convertible Debt
Debt Instrument [Line Items]
Short-term debt	0	1,000
Short-term note due November 2021 | Other Payables
Debt Instrument [Line Items]
Short-term debt	0	1,000
PPP loan | Notes Payable to Banks
Debt Instrument [Line Items]
Debt instrument, gross	$ 0	$ 161

DEBT - Narrative (Details)

DEBT - Narrative (Details)	Jun. 07, 2021USD ($)	Nov. 17, 2020USD ($)	Mar. 31, 2021USD ($)	Nov. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	May 26, 2020	May 14, 2020USD ($)debtInstrument	Mar. 24, 2016USD ($)$ / shares
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants					$ 12,700,000
Proceeds from issuance of notes and warrants, related party					$ 8,500,000
Repayment of debt						$ 2,000,000	$ 14,134,000
Term loan | Secured Debt
Debt Instrument [Line Items]
Principal amount	$ 10,000,000					10,000,000
Additional borrowing capacity available	$ 20,000,000					$ 20,000,000
Debt instrument, interest rate floor	7.25%
Interest rate at end of period						7.25%
Debt final payment fee, percentage	4.75%
Debt issuance costs, gross	$ 600,000
Term loan | Secured Debt | Prepayment before June 7, 2022
Debt Instrument [Line Items]
Debt instrument, prepayment fee, percentage	3.00%
Term loan | Secured Debt | Prepayment before June 7, 2023
Debt Instrument [Line Items]
Debt instrument, prepayment fee, percentage	2.00%
Term loan | Secured Debt | Prepayment after June 7, 2023
Debt Instrument [Line Items]
Debt instrument, prepayment fee, percentage	1.00%
Term loan | Secured Debt | Prime Rate
Debt Instrument [Line Items]
Variable interest rate spread	4.00%
Convertible promissory note due March 2021 | Convertible Subordinated Debt
Debt Instrument [Line Items]
Principal amount										$ 10,000,000
Debt instrument, term										5 years
Convertible debt instrument, conversion price (in dollars per share) | $ / shares										$ 91.02
Debt instrument, interest rate										6.00%
Short-term note due May 2021 | Convertible Debt
Debt Instrument [Line Items]
Debt instrument, interest rate								10.00%
Principal and interest converted to common stock		$ 13,100,000
PPP loan
Debt Instrument [Line Items]
Debt instrument, decrease, forgiveness			$ 100,000	$ 200,000
PPP loan | Notes Payable to Banks
Debt Instrument [Line Items]
Principal amount									$ 300,000
Number of debt instruments | debtInstrument									2
MYOS Promissory Note | Other Payables
Debt Instrument [Line Items]
Principal amount		3,000,000
Repayment of debt		$ 1,000,000

PHARMACY OPERATIONS EXPENSES (D

PHARMACY OPERATIONS EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Other Income and Expenses [Abstract]
Wages and salaries	$ 9,844	$ 4,486
Other pharmacy operations expenses	1,374	612
Depreciation of property, plant and equipment	826	655
Rent and utilities	558	275
Repairs and maintenance	316	97
Amortization of intangible assets	578	21
Total pharmacy operations expenses	$ 13,496	$ 6,146

GENERAL AND ADMINISTRATIVE EX_3

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Other Income and Expenses [Abstract]
Wages and salaries	$ 10,980	$ 9,682
Professional services	3,457	2,001
Insurance	1,780	503
Rent and utilities	1,338	1,242
Other general and administrative expenses	1,021	669
Share-based compensation	1,205	380
Software licenses and support	1,179	419
Travel and other employee expenses	736	359
Office and IT supplies	393	441
Depreciation of property, plant and equipment	188	167
Total general and administrative expenses	$ 22,277	$ 15,863

OTHER GAIN (LOSS) (Details)

OTHER GAIN (LOSS) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Other Income and Expenses [Abstract]
Forgiveness of PPP Loan	$ 161	$ 181
Other gain (loss), net	45	(291)
Total other gain (loss), net	$ 206	$ (110)

INCOME TAXES - Reconciliation (

INCOME TAXES - Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (43,813)	$ (26,810)
Income tax recovery at statutory rate (21%)	(9,201)	(5,630)
State income tax expense, net of federal benefit	(1,955)	0
Increase resulting from:
Effect of foreign tax rate	(610)	(252)
Unrecognized deferred tax asset	14,356	5,642
Permanent and other differences	(2,588)	240
Provision for income taxes	$ 2	$ 0

INCOME TAXES - Future Income Ta

INCOME TAXES - Future Income Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Future income tax assets:
Non-capital losses	$ 44,590	$ 31,658
Un-depreciated capital cost (UCC)	1,525	1,868
Other intangible items	1,556	223
Interest limitation carryforward	463	0
Total future income tax assets	48,134	33,749
Future income tax liabilities:
Unrecognized deferred tax asset	(48,134)	(33,749)	$ (27,672)
Net future income tax asset	$ 0	$ 0

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance	$ 14,385	$ 6,077
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	62,800
Operating loss carryforwards, subject to expiration	11,600
Operating loss carryforwards, not subject to expiration	51,200
Foreign Tax Authority | Canada Revenue Agency
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 103,800

INCOME TAXES - Rollforward of D

INCOME TAXES - Rollforward of Deferred Tax Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets, Valuation Allowance [Roll Forward]
Beginning balance	$ 33,749	$ 27,672
Additions based on tax positions related to the current year	14,385	6,077
Ending balance	$ 48,134	$ 33,749

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Concentration Risk [Line Items]
Contract liability			$ 4.7
Contract revenue recognized		$ 4.7
Revenue | Customer Concentration Risk | Healthcare Organization A
Concentration Risk [Line Items]
Concentration risk, percentage	25.00%
Revenue | Customer Concentration Risk | Healthcare Organization B
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%
Revenue | Customer Concentration Risk | Significant Customer
Concentration Risk [Line Items]
Concentration risk, percentage	34.00%
Accounts Receivable | Customer Concentration Risk | Three Payors
Concentration Risk [Line Items]
Concentration risk, percentage	61.00%
Accounts Receivable | Customer Concentration Risk | Two Payors
Concentration Risk [Line Items]
Concentration risk, percentage		37.00%
Hardware
Concentration Risk [Line Items]
Contract revenue recognized		$ 1.5
Other Revenue
Concentration Risk [Line Items]
Contract revenue recognized		$ 3.2

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - Supplier Concentration Risk - Inventories	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Vendor A
Concentration Risk [Line Items]
Concentration risk, percentage	32.00%	26.00%
Vendor B
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%	15.00%
Vendor C
Concentration Risk [Line Items]
Concentration risk, percentage	12.00%	0.00%

REDEEMABLE PREFERRED STOCK, D_3

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Preferred Stock Rollforward (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)shares	[1]
Increase (Decrease) in Temporary Equity [Roll Forward]
Temporary equity beginning balance (in shares) | shares	10,500,440
Temporary equity beginning balance | $	$ 93,484
Issued (in shares) | shares	102,777
Issued | $	$ 788
Converted to common shares in Merger (in shares) | shares	(10,603,217)
Converted to common shares in Merger | $	$ (94,272)
Temporary equity ending balance (in shares) | shares	0
Temporary equity ending balance | $	$ 0
[1]	$0.001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020.

REDEEMABLE PREFERRED STOCK, D_4

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Redeemable Preferred Stock, Narrative (Details) $ / shares in Units, $ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares		Dec. 31, 2019CAD ($)installmentshares		Dec. 31, 2020$ / sharesshares		Nov. 16, 2020shares
Class of Warrant or Right [Line Items]
Redeemable preferred shares, authorized (in shares)	10,000,000				10,000,000
Redeemable preferred shares, par value (in USD per share) | $ / shares	$ 0.001				$ 0.001
Redeemable preferred shares, outstanding (in shares)	0	[1]	10,500,440	[1]	0	[1]	10,603,217
Preferred stock affirmative vote threshold			60.00%
Preferred stock IPO conversion feature | $			$ 30
Preferred stock, redemption payment, number of annual installments | installment			3
Series C preferred stock
Class of Warrant or Right [Line Items]
Preferred stock full-ratchet adjustment term (in years)	3 years
Preferred stock aggregate gross proceeds | $	$ 10
Redeemable preferred shares, outstanding (in shares)							1,634,249
Series D preferred stock
Class of Warrant or Right [Line Items]
Preferred stock full-ratchet adjustment term (in years)	3 years
Preferred stock aggregate gross proceeds | $	$ 10
Redeemable preferred shares, outstanding (in shares)							502,630
Series E preferred stock
Class of Warrant or Right [Line Items]
Preferred stock full-ratchet adjustment term (in years)	3 years
Preferred stock aggregate gross proceeds | $	$ 10
Redeemable preferred shares, outstanding (in shares)							5,067,908
[1]	$0.001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020.

REDEEMABLE PREFERRED STOCK, D_5

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Schedule of Stock Conversion (Details)	Nov. 17, 2020shares	Dec. 31, 2021shares	[1]	Dec. 31, 2020shares	[1]	Nov. 16, 2020shares	Dec. 31, 2019shares	[1]
Class of Stock [Line Items]
Redeemable preferred shares, outstanding (in shares)		0		0		10,603,217	10,500,440
Common shares issued through conversion of preferred shares (in shares)	11,797,055
Series A preferred stock
Class of Stock [Line Items]
Redeemable preferred shares, outstanding (in shares)						1,175,544
Preferred stock conversion ratio	1
Common shares issued through conversion of preferred shares (in shares)	1,175,544
Series B preferred stock
Class of Stock [Line Items]
Redeemable preferred shares, outstanding (in shares)						2,222,886
Preferred stock conversion ratio	1
Common shares issued through conversion of preferred shares (in shares)	2,222,886
Series C preferred stock
Class of Stock [Line Items]
Redeemable preferred shares, outstanding (in shares)						1,634,249
Preferred stock conversion ratio	1.54
Common shares issued through conversion of preferred shares (in shares)	2,517,665
Series D preferred stock
Class of Stock [Line Items]
Redeemable preferred shares, outstanding (in shares)						502,630
Preferred stock conversion ratio	1.62
Common shares issued through conversion of preferred shares (in shares)	813,050
Series E preferred stock
Class of Stock [Line Items]
Redeemable preferred shares, outstanding (in shares)						5,067,908
Preferred stock conversion ratio	1
Common shares issued through conversion of preferred shares (in shares)	5,067,910
[1]	$0.001 par value, 10,000,000 shares authorized at December 31, 2021 and 2020.

REDEEMABLE PREFERRED STOCK, D_6

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Schedule of Preferred Stock Dividend Rights (Details)	12 Months Ended
	Dec. 31, 2019$ / shares
Series A preferred stock
Class of Stock [Line Items]
Annual dividend rate (in CAD per share)	$ 0.41
Series B preferred stock
Class of Stock [Line Items]
Annual dividend rate (in CAD per share)	0.57
Series C preferred stock
Class of Stock [Line Items]
Annual dividend rate (in CAD per share)	1.36
Series D preferred stock
Class of Stock [Line Items]
Annual dividend rate (in CAD per share)	1.42
Series E preferred stock
Class of Stock [Line Items]
Annual dividend rate (in CAD per share)	$ 0.88

REDEEMABLE PREFERRED STOCK, D_7

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Preferred Stock Liquidation Rights (Details)	Dec. 31, 2019$ / shares
Series A preferred stock
Class of Stock [Line Items]
Preferred stock, liquidation preference (in CAD per share)	$ 5.13
Series B preferred stock
Class of Stock [Line Items]
Preferred stock, liquidation preference (in CAD per share)	7.10
Series C preferred stock
Class of Stock [Line Items]
Preferred stock, liquidation preference (in CAD per share)	16.95
Series D preferred stock
Class of Stock [Line Items]
Preferred stock, liquidation preference (in CAD per share)	17.79
Series E preferred stock
Class of Stock [Line Items]
Preferred stock, liquidation preference (in CAD per share)	$ 11

REDEEMABLE PREFERRED STOCK, D_8

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Preferred Stock Conversion Price (Details)	Dec. 31, 2019$ / shares
Series A preferred stock
Class of Stock [Line Items]
Preferred stock, conversion price (in CAD per share)	$ 5.13
Series B preferred stock
Class of Stock [Line Items]
Preferred stock, conversion price (in CAD per share)	7.10
Series C preferred stock
Class of Stock [Line Items]
Preferred stock, conversion price (in CAD per share)	11
Series D preferred stock
Class of Stock [Line Items]
Preferred stock, conversion price (in CAD per share)	11
Series E preferred stock
Class of Stock [Line Items]
Preferred stock, conversion price (in CAD per share)	$ 11

REDEEMABLE PREFERRED STOCK, D_9

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Common Shares, Narrative (Details)	Nov. 17, 2020	Dec. 31, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares
Equity [Abstract]
Common shares, authorized (in shares)		100,000,000	100,000,000
Common shares, par value (in USD per share) | $ / shares		$ 0.001	$ 0.001
Stock split, conversion ratio	1.26
Granted (in shares)		1,003,130	442,830

REDEEMABLE PREFERRED STOCK, _10

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Share Based Compensation, Narrative (Details)	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2018serviceProvidershares	Mar. 29, 2022USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2018USD ($)shares	Dec. 31, 2019shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP | $			$ 72,000
Number of eligible service providers affected | serviceProvider	53
Options outstanding			2,848,903	2,439,020		2,391,401
Options granted (in shares)			1,003,130	442,830
Exercise price (in USD per share) | $ / shares			$ 6.07	$ 1.34
Share-based compensation | $			$ 1,205,000	$ 380,000
Expense remaining to be recognized | $			$ 3,600,000
Weighted average recognition period (in years)			3 years
Aggregate fair value of options vested | $			$ 1,200,000	300,000
Warrants issued during period			0
Exercise of warrants | $			$ 151,000	$ 12,000
Warrants (in shares)			737,335	1,677,555
Liability for future warrant issuance | $			$ 0	$ 0
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)		1,700,000
Fair value of options granted | $		$ 1,500,000
Fair value of RSUs granted | $		$ 1,400,000
Investor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants (in shares)			626,339
Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of warrants (in shares)			794,804	7,635
Exercise of warrants | $			$ 1,000
Common Shares | Investor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of warrants (in shares)			565,496
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards other than options granted (in shares)			852,395
Exercise price (in USD per share) | $ / shares			$ 6.07	$ 1.34
Restricted Stock Units (RSUs) | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards other than options granted (in shares)		1,200,000
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation | $			$ 100,000	$ 0
Minimum | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (in dollars per share) | $ / shares		$ 0.83
Maximum | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (in dollars per share) | $ / shares		$ 1.38
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)				5,000,000
Shares reserved for future issuance, minimum annual increase (in shares)				5,000,000
Common stock available for grant (in shares)			3,400,000
2020 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent increase in shares available under ESPP, prior year				5.00%
2020 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)				700,000
Shares reserved for future issuance, minimum annual increase (in shares)				1,000,000
Common stock available for grant (in shares)			1,000,000
ESPP (in shares)			42,739
2020 ESPP | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent increase in shares available under ESPP, prior year				1.00%
2012 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exchanged under plan (in shares)	239,181
Options outstanding			5,777
2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exchanged under plan (in shares)	1,269,180
One-time incremental compensation cost | $					$ 1,000,000
Number of shares authorized for issuance (in shares)					1,972,530
Maximum option term					10 years
Vesting term					4 years

REDEEMABLE PREFERRED STOCK, _11

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Option Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	1,003,130	442,830
Weighted average grant date fair value of awards (in USD per share)	$ 3.32	$ 0.72
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%	6.00%
Grant price (in USD per share)	$ 1.70	$ 1.34
Market price (in USD per share)	$ 1.70	$ 1.34
Volatility	60.00%	60.00%
Risk Free Rate	0.46%	0.43%
Dividend Yield	0.00%	0.00%
Expected life (in years)	5 years 2 months 1 day	5 years 10 months 13 days
Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%	6.00%
Grant price (in USD per share)	$ 6.07	$ 1.34
Market price (in USD per share)	$ 6.07	$ 1.34
Volatility	60.00%	60.00%
Risk Free Rate	1.12%	0.43%
Dividend Yield	0.00%	0.00%
Expected life (in years)	5 years 11 months 8 days	5 years 11 months 1 day
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%	6.00%
Grant price (in USD per share)	$ 15.15	$ 1.34
Market price (in USD per share)	$ 15.15	$ 1.34
Volatility	60.00%	60.00%
Risk Free Rate	1.36%	0.44%
Dividend Yield	0.00%	0.00%
Expected life (in years)	6 years	6 years 7 days

REDEEMABLE PREFERRED STOCK, _12

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - RSU Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%	6.00%
Grant price (in USD per share)	$ 1.70	$ 1.34
Market price (in USD per share)	$ 1.70	$ 1.34
Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%	6.00%
Grant price (in USD per share)	$ 6.07	$ 1.34
Market price (in USD per share)	$ 6.07	$ 1.34
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%	6.00%
Grant price (in USD per share)	$ 15.15	$ 1.34
Market price (in USD per share)	$ 15.15	$ 1.34
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	852,395
Grant date fair value of awards granted (in USD per share)	$ 3.35
Restricted Stock Units (RSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%
Grant price (in USD per share)	$ 0
Market price (in USD per share)	1.70
Restricted Stock Units (RSUs) | Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value of awards granted (in USD per share)	$ 3.35
Unvested Forfeiture Rate	6.00%
Grant price (in USD per share)	$ 0
Market price (in USD per share)	$ 3.35
Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested Forfeiture Rate	6.00%
Grant price (in USD per share)	$ 0
Market price (in USD per share)	$ 15.15

REDEEMABLE PREFERRED STOCK, _13

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Awards
Outstanding awards at beginning of period (in shares)	2,439,020	2,391,401
Granted (in shares)	1,003,130	442,830
Shares issued for options exercises (in shares)	(237,330)	(160,090)
Awards cancelled/forfeited (in shares)	(335,971)	(235,121)
Expired (in shares)	(19,946)
Outstanding awards at end of period (in shares)	2,848,903	2,439,020
Awards vested and exercisable (in shares)	1,834,645	1,745,376
Awards vested and unvested exercisable (in shares)	1,834,645	1,745,376
Awards vested and expected to vest (in shares)	2,754,222	2,386,417
Weighted Average Exercise Price
Weighted average exercise price of awards outstanding at beginning of period (in USD per share)	$ 1.56	$ 1.59
Weighted average exercise price of awards granted (in USD per share)	6.07	1.34
Weighted average exercise price of awards exercised/released (in USD per share)	1.67	1.84
Weighted average exercise price of awards cancelled/forfeited (in USD per share)	4.75	1.63
Weighted average exercise price of awards expired (in USD per share)	1.65
Weighted average exercise price of awards outstanding at end of period (in USD per share)	2.78	1.56
Weighted average exercise price of awards vested and exercisable (in USD per share)	1.95	1.63
Weighted average exercise price of awards vested and unvested exercisable (in USD per share)	1.95	1.63
Weighted average exercise price of awards vested and expected to vest (in USD per share)	2.74	1.57
Weighted average share price on date of exercise (in USD per share)	9.90	11.09
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	0.76	0.76
Grant date fair value of options granted (in USD per share)	3.32	0.72
Weighted average fair value of awards exercised/released (in USD per share)	0.81	0.98
Weighted average fair value of awards cancelled/forfeited (in USD per share)	2.58	0.76
Weighted average fair value of awards expired (in USD per share)	0.77
Weighted average fair value of awards outstanding at end of period (in USD per share)	1.44	0.76
Weighted average fair value of awards vested and exercisable (in USD per share)	0.95	0.78
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	0.95	0.78
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 1.42	$ 0.76
Weighted Average Remaining Contractual Life (Years)
Outstanding, end of period	7 years 7 months 9 days	8 years 2 months 12 days
Vested and exercisable, end of the period	6 years 7 months 20 days	7 years 10 months 24 days
Vested and unvested exercisable, end of the period	6 years 7 months 20 days	7 years 10 months 24 days
Vested and expected to vest, end of the period	7 years 6 months 18 days	8 years 2 months 12 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period	$ 32,894	$ 0
Aggregate intrinsic value of awards granted	0	4,960
Aggregate intrinsic value of awards exercised/released	1,954	1,482
Aggregate intrinsic value of awards cancelled/forfeited	392	2,886
Aggregate intrinsic value of awards expired	20
Aggregate intrinsic value of awards outstanding at end of period	31	32,894
Aggregate intrinsic value of awards vested and exercisable	24	23,428
Aggregate intrinsic value of awards vested and unvested exercisable	24	23,428
Aggregate intrinsic value of awards vested and expected to vest	$ 31	$ 32,175

REDEEMABLE PREFERRED STOCK, _14

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Nonvested Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Awards
Unvested outstanding, beginning of period (in shares)	693,644	712,559
Granted (in shares)	1,003,130	442,830
Cancelled/forfeited (in shares)	(333,565)	(18,481)
Expired (in shares)	(19,946)
Vested (in shares)	(329,005)	(443,264)
Unvested outstanding, end of period (in shares)	1,014,258	693,644
Weighted Average Exercise Price
Weighted average exercise price of unvested awards, beginning balance (in USD per share)	$ 4.28	$ 1.40	$ 1.44
Weighted average exercise price of awards granted (in USD per share)	6.07	1.34
Weighted average exercise price of awards cancelled/forfeited (in USD per share)	4.77	1.54
Weighted average exercise price of awards expired (in USD per share)	1.65
Weighted average exercise price of awards vested (in USD per share)	3.36	1.44
Weighted average exercise price of unvested awards, ending balance (in USD per share)	4.28	1.40
Weighted Average Grant Date Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	0.69	0.68
Grant date fair value of options granted (in USD per share)	3.32	0.72
Weighted average grant date fair value of awards cancelled/forfeited (in USD per share)	2.59	0.76
Weighted average grant date fair value of awards expired (in USD per share)	0.77
Weighted average grant date fair value of awards vested (in USD per share)	1.71	0.72
Weighted average fair value of awards outstanding at end of period (in USD per share)	$ 2.34	$ 0.69
Weighted average remaining contractual life of awards vested and unvested exercisable (in years)	3 years 1 month 9 days	2 years 6 months

REDEEMABLE PREFERRED STOCK, _15

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - RSU Activity (Details) - Restricted Stock Units (RSUs) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Number of Awards
Outstanding awards at beginning of period (in shares) | shares	0
Granted (in shares) | shares	852,395
Shares issued for options exercises (in shares) | shares	(11,155)
Awards cancelled/forfeited (in shares) | shares	(38,500)
Outstanding awards at end of period (in shares) | shares	802,740
Awards vested and exercisable (in shares) | shares	0
Awards vested and unvested exercisable (in shares) | shares	0
Awards vested and expected to vest (in shares) | shares	717,476
Weighted Average Exercise Price
Weighted average share price on date of exercise (in USD per share)	$ 1.93
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	0
Weighted average grant date fair value of options granted (in USD per share)	3.35
Weighted average fair value of awards exercised/released (in USD per share)	11.58
Weighted average fair value of awards cancelled/forfeited (in USD per share)	12.83
Weighted average fair value of awards outstanding at end of period (in USD per share)	2.78
Weighted average fair value of awards vested and exercisable (in USD per share)	0
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	0
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 2.81
Weighted Average Remaining Contractual Life (Years)
Vested and expected to vest, end of the period	4 years 10 months 24 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period | $	$ 0
Aggregate intrinsic value of awards granted | $	2,858
Aggregate intrinsic value of awards exercised/released | $	22
Aggregate intrinsic value of awards cancelled/forfeited | $	138
Aggregate intrinsic value of awards outstanding at end of period | $	1,124
Aggregate intrinsic value of awards vested and exercisable | $	0
Aggregate intrinsic value of awards vested and unvested exercisable | $	0
Aggregate intrinsic value of awards vested and expected to vest | $	$ 1,005

REDEEMABLE PREFERRED STOCK, _16

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Nonvested RSU Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Awards
Unvested outstanding, beginning of period (in shares)	0
Granted (in shares)	852,395
Cancelled/forfeited (in shares)	(38,500)
Vested (in shares)	(11,155)
Unvested outstanding, end of period (in shares)	802,740
Weighted Average Exercise Price
Weighted average exercise price of unvested awards, beginning balance (in USD per share)	$ 2.78	$ 0
Weighted average grant date fair value of options granted (in USD per share)	3.35
Weighted average fair value of awards cancelled/forfeited (in USD per share)	12.83
Weighted average grant date fair value of awards vested (in USD per share)	11.58
Weighted average exercise price of unvested awards, ending balance (in USD per share)	$ 2.78
Weighted average remaining contractual life of awards vested and unvested exercisable (in years)	2 years 8 months 12 days

REDEEMABLE PREFERRED STOCK, _17

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Share Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Share-based compensation	$ 1,205	$ 380

REDEEMABLE PREFERRED STOCK, _18

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Schedule of Warrants Issued (Details) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Term of warrants (in years)	7 years 7 months 6 days	7 years 9 months 18 days
Exercise price of warrants issued (in USD per share)	$ 1.56	$ 1.97
Warrants Issued February 11, 2020, Exercise Price $1.98
Class of Warrant or Right [Line Items]
Warrants (in shares)		27,427
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued February 11, 2020, Exercise Price $0.01
Class of Warrant or Right [Line Items]
Warrants (in shares)		309,698
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 0.01
Warrants Issued February 19, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		6,855
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued May 26, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		115,374
Term of warrants (in years)		6 months
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued June 4, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		16,119
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued June 9, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		1,676
Term of warrants (in years)		6 months
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued June 10, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		761
Term of warrants (in years)		6 months
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued June 17, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		319
Term of warrants (in years)		6 months
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued June 29, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		84,911
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 0.01
Warrants Issued July 2, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		2,285
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued August 14, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		1,524
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued August 21, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		2,285
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued October 2, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		6,857
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued October 6, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		61,331
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued October 7, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		381
Term of warrants (in years)		10 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued November 12, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		201,648
Term of warrants (in years)		8 years
Exercise price of warrants issued (in USD per share)		$ 1.57
Warrants Issued November 18, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)		58,518
Term of warrants (in years)		5 years
Exercise price of warrants issued (in USD per share)		$ 0.01

REDEEMABLE PREFERRED STOCK, _19

REDEEMABLE PREFERRED STOCK, DEFICIT AND SHARE-BASED COMPENSATION EXPENSE - Schedule of Outstanding Warrants (Details) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	737,335	1,677,555
Exercise price of warrants (in CAD per share)	$ 1.56	$ 1.97
Term of warrants (in years)	7 years 7 months 6 days	7 years 9 months 18 days
Common
Class of Warrant or Right [Line Items]
Warrants (in shares)	19,310	571,355
Exercise price of warrants (in CAD per share)	$ 0.01	$ 0.01
Common
Class of Warrant or Right [Line Items]
Warrants (in shares)	0	288,352
Exercise price of warrants (in CAD per share)	$ 6.93	$ 6.93
Common
Class of Warrant or Right [Line Items]
Warrants (in shares)	224,852	260,250
Exercise price of warrants (in CAD per share)	$ 1.66	$ 1.66
Common
Class of Warrant or Right [Line Items]
Warrants (in shares)	493,173	557,598
Exercise price of warrants (in CAD per share)	$ 1.57	$ 1.57

REVENUE AND SEGMENT REPORTING -

REVENUE AND SEGMENT REPORTING - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Revenue from External Customer [Line Items]
Number of reportable segments | segment	2
Contract liability			$ 4.7
Contract revenue recognized		$ 4.7
Hardware
Revenue from External Customer [Line Items]
Contract revenue recognized		1.5
Other Revenue
Revenue from External Customer [Line Items]
Contract revenue recognized		$ 3.2

REVENUE AND SEGMENT REPORTING_2

REVENUE AND SEGMENT REPORTING - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from External Customer [Line Items]
Total revenue	$ 22,129	$ 13,968
Total cost of products sold and services	21,812	8,805
Segment gross profit	317	5,163
Operating expense:
Pharmacy operations	13,496	6,146
General and administrative	22,277	15,863
Selling and marketing	7,204	3,283
Research and development	849	682
Merger expenses	0	4,691
Total operating expense	43,826	30,665
Operating loss	(43,509)	(25,502)
Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	20,203	7,728
Total cost of products sold and services	20,031	7,744
Segment gross profit	172	(16)
Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	1,926	6,240
Total cost of products sold and services	1,781	1,061
Segment gross profit	145	5,179
Total pharmacy and hardware revenue
Revenue from External Customer [Line Items]
Total revenue	21,119	10,596
Total cost of products sold and services	21,306	8,593
Total pharmacy and hardware revenue | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	20,203	7,728
Total pharmacy and hardware revenue | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	916	2,868
Retail pharmacy revenue
Revenue from External Customer [Line Items]
Total revenue	20,203	7,728
Retail pharmacy revenue | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	20,203	7,728
Retail pharmacy revenue | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	0	0
Hardware
Revenue from External Customer [Line Items]
Total revenue	470	2,401
Hardware | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Hardware | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	470	2,401
Subscription
Revenue from External Customer [Line Items]
Total revenue	446	467
Subscription | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Subscription | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	446	467
Total service revenue
Revenue from External Customer [Line Items]
Total revenue	1,010	3,372
Total cost of products sold and services	506	212
Total service revenue | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Total service revenue | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	1,010	3,372
Software integration
Revenue from External Customer [Line Items]
Total revenue	0	3,168
Software integration | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Software integration | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	0	3,168
Software
Revenue from External Customer [Line Items]
Total revenue	259	44
Software | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Software | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	259	44
Maintenance and support
Revenue from External Customer [Line Items]
Total revenue	161	58
Maintenance and support | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Maintenance and support | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	161	58
Installation
Revenue from External Customer [Line Items]
Total revenue	39	55
Installation | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Installation | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	39	55
Professional services and other
Revenue from External Customer [Line Items]
Total revenue	551	47
Professional services and other | Retail Pharmacy Services
Revenue from External Customer [Line Items]
Total revenue	0	0
Professional services and other | Pharmacy Technology
Revenue from External Customer [Line Items]
Total revenue	$ 551	$ 47

REVENUE AND SEGMENT REPORTING_3

REVENUE AND SEGMENT REPORTING - Schedule of Assets and Liabilities by Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 38,143	$ 69,331
Total liabilities	19,070	8,264
Operating Segments | Retail Pharmacy Services
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	13,641	6,012
Total liabilities	5,618	2,203
Operating Segments | Pharmacy Technology
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	5,222	5,547
Total liabilities	3,567	3,422
Corporate
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	19,280	57,772
Total liabilities	$ 9,885	$ 2,639

REVENUE AND SEGMENT REPORTING_4

REVENUE AND SEGMENT REPORTING - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 8,230	$ 5,034
United States
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	7,675	4,533
Canada
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 555	$ 501